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ABSTRACT 
Background 
Each year hip arthroplasties increase the quality of life for over 1 million patients worldwide. 
Although the complication rates are low, the absolute numbers are rising as the numbers of procedures 
increase. Prosthetic joint infections resulting from intraoperative contamination are regarded as 
compensable by the Swedish patient insurance. Healthcare personnel are obliged to inform patients 
about their injury and the possibility to claim it. In this thesis aspects of two complications after hip 
arthroplasty are discussed. Both have gone from being relatively frequent complications of uncommon 
procedures in the early days of hip arthroplasty, to infrequent complications of common procedures, 
resulting in many suffering patients. Prosthetic joint infection (Study I – III) is the most feared 
complication and venous thromboembolism is the most common medical complication, (Study IV). 
Methods 
Studies I and II are based on outcomes of operations performed at the Department of Orthopaedics, 
Stockholm South General Hospital (Södersjukhuset). Studies III and IV cover the nationwide 
population of Sweden and are based on data from national quality and healthcare registers. 
Study I: 3 884 patients operated between 1996 and 2005, due to degenerative hip disorder or hip 
fracture (primary and secondary fracture prostheses) were analysed for the incidence, microbiology 
and outcome of prosthetic joint infection after hip arthroplasty. 
Study II: Air quality in the operating room was evaluated through comparison of three clothing 
systems through 244 measurements of colony forming units per square meter, during 37 operations. 
Study III: A national cohort of prosthetic infections after total hip arthroplasties in patients operated 
between 2005 and 2008 has previously established. We analysed the number of filed patient claims in 
441 infections and examined the incidence and outcome (accepted, rejected, approved disability). 
Study IV: Low molecular weight heparins and new oral anticoagulants were compared as 
thromboprophylaxis after 32 663 elective hip arthroplasties, through determination of effectiveness as 
incidence of venous thromboembolic events and assessment of safety by analysis of bleedings, 
reoperations and mortality. 
Results 
Study I: The infection rates for degenerative hip disorder and primary and secondary fracture 
prostheses were 0.4%, 2.1% and 2.5% respectively. The patient factors associated with a significantly 
increased risk for developing a surgical-site infection were both fracture indication for surgery and 
male gender. Staphylococcus Aureus and Coagulase-Negative Staphylococci dominated as 
microbiological agents. Treatment of 27 (44%) patients resulted in permanent resection arthroplasty, 
of which 22 (81%) were fracture patients. 
Study II: Compared with the two other reusable suits, the significantly lowest values of colony 
forming units were observed with the single-use polypropylene BARRIER® Clean Air Suit. 
Study III: 329 (75%) of patients did not file a claim of injury to LÖF and of those 112 that did, 108 
(96%) were accepted as eligible for compensation. Patients’ age above 72 years and fracture diagnosis 
were the only significant factors associated with not filing a claim of injury. 
Study IV: Compared to low molecular weight heparins, new oral anticoagulants reduced the risk of 
venous thromboembolic events with more than 50% with simultaneously remained safety profile. In 
the subset of patients treated with low molecular weight heparins no significant difference with 
regards to the studied outcomes was observed. 
Conclusion 
Patients with fractures of the neck of femur, treated with primary or secondary fracture prostheses, 
have a greater risk of infection and display worse outcomes compared with patients operated due to 
degenerative hip disorders. Additionally, among the overall low rate of patient claims, fracture 
patients stand out with an even greater share of non-claimants (87%). Healthcare personnel should 
increase their knowledge about LÖF. Improving air quality is difficult in existing facilities. Evaluation 
of clothing in real-life surgical environments can, by decreased counts of airborne bacteria, result in 
better prevention of infections. Compared to low molecular weight heparins, thromboprophylaxis with 
new oral anticoagulants extending for a minimum of 28 days is a superior regimen for the majority of 
patients undergoing elective primary total hip arthroplasty. 
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1 INTRODUCTION 
 
1.1 HISTORICAL REVIEW 
 
1.1.1 Thromboembolism 
 
The history of complications and concepts of this thesis begins with Abu Ali al-Husayn ibn Abd Allah 
ibn Sina (980 - 1037), known as Avicenna in Europe, a Persian physician, philosopher and scientist, 
who completed his book The Canon of Medicine in 10351. It set the standards for medicine and was 
used as a textbook for over 700 years. Avicenna described numerous and various conditions and 
treatments, therein also a partial description of the clinical picture of deep vein thrombosis (DVT) and 
recommended open surgical thrombectomy2. He also cautioned that “care should be taken while 
cleaning the veins from the obstructing material or the particles might migrate to the upper organs”. 
In 1271 Guillaume de Saint Pathus reported what is believed to be the first description and treatment 
of DVT in “La vie et les miracles de Saint Louis”3. A young cobbler, Raoul of Normandy, suffered 
unilateral pain and swelling of his right calf that progressed proximally to the thigh. He was initially 
advised to wait but developed an ulcer and was exposed to several unsuccessful treatment attempts. 
Eventually advice was given to visit the tomb of King Saint Louis, where Raoul spent several days 
praying to the saint. During his stay, he collected the dust from the stone covering the tomb and 
applied it directly on the ulcer. This cured Raoul´s condition and he lived for another 11 years. 
During the Renaissance, pregnancy was the only reported cause of DVT and was considered as a 
consequence of retention of “evil humors” or menstrual blood4. Discharge of these humors was 
performed by bloodletting, a popular treatment method of that time5. On the contrary, the cause of 
postpartum DVT was believed to be retention of unconsumed milk (“milk leg”) and breast-feeding 
was encouraged as prophylaxis against DVT3. In 1676, Richard Wiseman hypothesized why blood 
might clot by describing two of the three factors that later came to constitute Virchow’s triad, stasis 
and hypercoagulability: “Blood, which being transmitted into the veins, either by reason of the 
depending of the part, or from some other pressure upon the vessel, or else by its own grossness, 
proves unapt for circulation. Then instead of continuing its current to the other parts, it stops in the 
place and coagulates”6. In 1784 James Hunter performed the first venous ligations above thromboses, 
to prevent extension of clots7. However traditional treatments as bloodletting via application of 
leeches were generally considered as more effective to relieve congestion and inflammation8. 
Generally before the discovery of heparin, treatment for DVT mainly relied on bed rest with limbs in 
iron splints to prevent the thromb from migration, elevation of the involved leg to favour venous 
return and application of heat to reduce vasospasm and increase collateral circulation7. 
In 1856 Rudolf Ludwig Virchow described the famous triad of factors contributing to development of 
venous thrombosis: hypercoagulability, stasis and vascular injury. It is doubtful however if the triad 
was originally described as presented today, in contemporary medical literature. Virchow focused his 
research on pulmonary embolism (PE) and coined the terms “embolism” and “thrombosis” but it took 
almost one hundred years before he was credited for the triad explaining the formation of thrombi6. 
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In 1872, Trendelenburg, founder of the German Surgical Society, developed the left parasternal 
thoracotomy for acute treatment of PE, accessing the pulmonary artery for removal of the embolus. 
His pupil, professor Kirschner, could later report a successful procedure in 1924, yielding widespread 
enthusiasm. During the following decade 300 acute pulmonary embolectomies were performed in 
Germany with only 10 survivors9. 
The path of non-surgical treatment and prophylaxis of thromboembolism is complex. Already 
Hippocrates, in ancient Greece, recommended chewing salicylate-containing willow leaves for 
analgesia in childbirth. Description of salicylates can also be found throughout the Middle Ages and 
their use is likewise reported by Europeans in the New World, on the advice of Native Americans10. 
Charles Gerhardt in France was the first to synthesize acetylsalicylic acid (ASA) in 1853, but the 
agent was initially ignored. Eventually the salicylate trail led to the Bayer Company in Germany that 
introduced the analgesic and antipyretic drug commercially in 1899, under the name aspirin10. In 1967 
Weiss discovered the inhibition of platelet activation11. Following, in 1971, Vane published his 
findings of aspirin´s inhibition of prostaglandin synthetase12 and was later awarded the Nobel Prize in 
Medicine. Simultaneously clinical reports proved the drugs efficacy in prevention cerebral transient 
ischemic attacks13. The following trials in the 70s and 80s confirmed ASA prophylactic properties 
against venous thromboembolism (VTE)14,15. 
Heparin was discovered in 1916 by a medical student, McLean, and his supervisor, Howell, continued 
the work of purification16. Finally three teams from Toronto, Stockholm and Copenhagen were 
working independently to further isolate, purify and achieve a reliable and stable substance10. In 1935 
Erik Jorpes purified and solved the chemical structure in Stockholm17. Later the same year Hedenius 
and Wilander tested heparin on human volunteers and Clarence Crafoord started treatment of general 
surgery patients at Sabbatsberg Hospital in Stockholm18. This led to fast spread of this effective 
thromboprophylaxis (TP), which later also played a significant roll in the broader introduction of hip 
arthroplasties. After the discovery of heparin fractions’ higher ratio of anti-factor Xa activity, synthetic 
preparation of low molecular weight heparin (LMWH) begun in the 70s. LMWHs were introduced in 
Europe in the 80s and were granted approval in the United States in 199310. 
As heparin was introduced, coumarin was also discovered in 1940s. It started in 1921 with a 
mysterious haemorrhagic disease of cattle after ingestion of spoiled sweet clover in North Dakota and 
Alberta. Karl Paul Link linked the disease to coumarin and described its properties. In 1940, he 
continued with developing his well-known rodenticide. After an unsuccessful suicide attempt of a 
navy inductee, Link realized that this drug was not as toxic as initially believed19. The complementary 
mechanism of fast acting heparin and the slower coumarin allowed for sequential use in DVT 
treatment, already described in the late 1940s20. 
The introduction of new oral anticoagulants (NOAC) represents the most recent advancement in TP. 
The first approvals for drugs in this group, dabigatran and rivaroxaban, were granted in 2008 in 
Europe and two years later in the United States. 
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1.1.2 Hip arthroplasty 
 
Generally hip arthroplasties are classified based on two aspects. The first classification is based on the 
implanted components; total hip arthroplasty (THA) replaces both the head of femur and the pelvic 
acetabulum with separate components, whereas in hemiarthroplasty (HA) only the head of femur is 
replaced. The second classification is based on the method of fixation. In cemented fixation bone 
cement made of polymethyl methacrylate is used as a mantle interface between the bone and the 
implant. Uncemented implants are instead covered with special surface coatings, which facilitates the 
bone to remodel and bond to the implant. Both cemented and uncemented arthroplasties have proven 
their excellent results and long-term survival21,22 and the choice of fixation depends on both patient 
factors and the preference of individual surgeons. 
However, the era of surgical treatment of painful osteoarthritis started in the late 19th century with an 
interpositional arthroplasty. Various tissues, including fascia lata, skin, and even submucosa of pig´s 
urinary bladders, were placed between the articulating surfaces of the hip joint in attempt to relief 
pain23. Marius Nygaard Smith-Petersen was a Norwegian born surgeon that heralded the era of hip 
arthroplasty. He emigrated to the USA at age 16, where he studied medicine and received his surgical 
training. In 1923 he introduced his original arthroplasty design, a hollow hemisphere of glass that 
could fit over the femoral head. The intension was to stimulate cartilage regeneration on both sides 
and remove the glass mould after the cartilage had been restored. The glass could not withstand the 
weight bearing stresses and experimentation with various materials followed in the 1930s. After 
suggestion from his dentist, Smith-Petersen developed the Vitallium cup in 1938 and perfected the 
operation through design of instruments and techniques24. 
The French brothers, Jean and Robert Judet, introduced the first HA in 1940s. They removed the 
femoral head and replaced it with one made of acrylic resin. Early results were brilliant but the resin 
was also too weak and the fit was not perfect, which resulted in subsequent failure25. 
Philip Wiles overcame some of these difficulties with the first THA. The stainless-steel acetabular cup 
and femoral head fitted each other and the head was anchored in a lateral plate through a sliding stem. 
Due to reduced movement and bone absorption, Wiles could only report satisfactory results in 2 out of 
8 patients25. 
In the 50s many surgeons experimented with different designs and materials. The most famous is the 
Austin Moore HA prosthesis26, which through modifications, is still used today in fracture surgery of 
the neck of femur.  
Sir John Charnley is considered to be the father of modern hip arthroplasty. In 1961 he opened the 
well-known hip centre in Wrightington and his revolutionary principles of the low friction arthroplasty 
concept were published the same year27. Charnley’s three major contributions to the evolution of THA 
were the idea of low friction torque between the components, rigid fixation of component to bone 
through acrylic cement and the use of high-density polyethylene as bearing material23. His structured 
follow-up of patients and meticulously collected data enabled further development in surgical 
technique, implant design and postoperative care28. 
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Due to the considerable amount of surgical-site infections (SSI), Charnley was also devoted to 
prevention of infections and improving air quality of the operating room29. However not everyone 
accepted Charnley’s concepts and early failures of cemented stems were frequent. The observed 
osteolysis led to the assumption that premature loosening was related to the so-called cement 
disease30. In retrospective, it is believed that this frequent phenomenon was due to the initially 
deficient cementation technique. This led to further development of uncemented components23. 
Nevertheless Charnley’s work is still highly relevant today and constitutes the basis of modern hip 
arthroplasty design and surgery. 
Many years of development and improvement made the long survival of today’s hip arthroplasties 
possible. Each year the procedure brings an increased quality of life to over 1 million patients 
worldwide31. The main indication for surgery is still primary osteoarthritis but many other conditions 
are also threated with arthroplasties. Therefore THA can be considered “the operation of the 
century”23 and the number of annually implanted arthroplasties continues to grow32,33. Today´s choice 
of implants is almost infinite. However not every implant is used in every country and the preferences 
are based on traditions, experience, price and methods of assessment of their survival and outcomes. 
In Sweden above 20 000 arthroplasties are performed each year, out of which 16 500 are THAs, and 4 
000 are HAs21. The most predominant indication for THA is osteoarthritis which results in 13 700 
operations per year, where as approximately 1 400 patents are operated due to an acute fracture. The 
remaining 1 400 are patients with femoral head necrosis, complications to previous fracture treatment, 
paediatric diseases, malignancies and inflammatory diseases. The HAs are mainly operated for 
fractures in fragile or older patients. Additionally, patients with unsuccessful outcomes of previous 
fracture treatments as well as fragile patients suffering from malignancies may receive a HA. 
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1.1.3 Airborne contamination 
 
Florence Nightingale, an English nurse named after her city of birth, started to practice her ideas 
during the Crimean War in 1854. She was also a statistician and manager that realised the importance 
of good ventilation, hygiene, nutrition as well as organization of supplies. Nightingale observed that 
far more soldiers died from infections than from the wounds suffered on the battlefield. She 
introduced bathing of wounds with clean individual cloths and cross-contamination was reduced by 
separate beds. Her managing skills and efforts on hygiene resulted in a drop of mortality from 33% to 
2%34. 
Around the same time Ignaz Philipp Semmelweis was gathering sanitary observations at the 
Allgemeine Krankenhaus in Vienna. There were two maternity clinics at this hospital. Medical 
students performed deliveries in the first clinic and midwifes in the second. Although the same patient 
population was treated and the same corridors and linen were used, the mortality rates at the first clinic 
exceeded the second 10-fold. The admitted street-births also had lower mortality rates, independently 
of the clinic of admission. The explanation of this difference in survival rates was the educational 
encouragement of medical students to learn from the mortuary. After the handling of corpses they 
would return to clinic and examine the patients. Introduction of hand disinfection before vaginal 
examination reduced mortality to the levels of the second clinic. Semmelweis also observed similar 
contamination in surgical wounds. His conclusion that doctors’ hands were the carriers of diseases 
was not easy to accept and it took 13 years before his observations were published in 186135. 
The discoveries of the French biologist Louis Pasteur in 1850s and 60s provided direct support for the 
germ theory36 and inspired the British surgeon Joseph Lister. At that time most of the operations were 
followed by hospital gangrene and death was believed to be inevitable or coincidental. As in Vienna, 
surgeons rarely washed their hands and instruments were only wiped clean. Lister observed that 
infections were more prevalent in in-hospital patients and noted that more then half of patients with 
their bones exposed to air died. In 1867 he published his first paper on antiseptic treatment of open 
fractures with carbolic acid. Consequently Lister begun to sterilize instruments and hands. He 
developed a sterilized catgut ligature and a steam-operated carbolic acid spray for purification of 
contaminated air in the operating room37.  
The first observation on airborne bacteria and their influence on infection was published in 1946, 
based on observations during changing of dressings in a burns unit38. In 1960 Blower and Crew 
defined principles for design of ventilation: filtration of input air and adjusted air pressure gradients to 
force airflow from cleaner to dirtier zones39. In the same decade Charnley contributed with his work 
on clean air enclosures of glass and drapes, keeping the anaesthetist out of the clean area. He 
improved ventilation and introduced body suits. In the beginning of the 70s Charnley had achieved 
infection rates of well below 1%40. In 1975 Noble found that during walking 40 000 skin scales/min 
are released and about 10% of these carry bacteria41. Both aerobes and anaerobes can survive long 
enough to make an airborne route of infection possible42. The first recommendations for operating 
rooms were published in 1983 in UK, based to a large extend on Lidwell’s studies on air quality and 
bacteria carrying particles. He found an association between airborne bacteria and incidence of PJI in 
hip and knee arthroplasties43 and concluded that ultra clean air with less then 10 colony forming units 
per square meter (CFU)/m3 together with prophylactic antibiotics prevents almost all prosthetic joint 
infections (PJI) in THA surgery. 
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1.2 BACKGROUND 
 
1.2.1 Prosthetic joint infections after hip arthroplasty 
 
Following aseptic loosening and dislocation of prostheses PJI is the third most frequent complication 
in THA surgery21,44. Moreover, PJIs possibly result in the highest economic burden for the healthcare 
systems45,46 and cause the greatest suffering for patients47,48. The literature presents a great variation of 
incidence of PJI, ranging from 0.2% up to 9.0%49-56. This difference can be explained by different 
populations, follow up time and indications for surgery. The risk of PJI does not show a further 
decrease and some studies have even reported an increase57,58. It is difficult to explain this finding but 
most probably it is a multifactorial phenomenon. More fragile patients receive a hip arthroplasty today 
than before, which increases the risk of PJI. We have also become more aware of the serious 
consequences of PJI and have access to better diagnostic tools resulting in more successful 
diagnostics. The treatment has also become more aggressive, with consequently higher reoperation 
rates. Finally the increased reporting and catchment of registers in healthcare may play a role. 
PJI can be classified into 3 groups, depending on the time of diagnosis. The first group, early 
infections, are diagnosed during the first 3 postoperative months. The second group are delayed 
infections occurring between 3 and 24 months after the primary operation and consequently the third 
group, late infections, occur beyond 24 months59. The early and delayed infections are most often 
regarded as SSIs, resulting from intra- or perioperative contamination. Similarly, late infections are 
often a result of haematogenous spread (HS). The type and aggressiveness of bacteria is related to the 
emergence of symptoms. Coagulase negative staphylococcus and staphylococcus aureus are the most 
common bacteria in PJI59,60 and do not generally cause aggressive infections. This yields a diagnostic 
challenge. Additionally, the formation of biofilm is also an important aspect endangering curative 
outcome61,62. 
The treatment of PJI often includes long hospital stays with possibly several reoperations and long 
lasting antibiotic treatments. There is no consensus regarding preferred treatment strategies but the 
time of diagnosis, type of bacteria and patient factors must be taken into account. Some patients may 
even need removal of their implant, a resection arthroplasty63, in order to enable resolution of the 
infection. Although this procedure is often followed by insertion of a new prosthesis in the so-called 
two-staged treatment, the patients’ general condition does not always allow for the second stage, 
resulting in a permanent resection arthroplasty. Previous studies have reported an incidence of this 
outcome of up to 32%56. Although permanent resection arthroplasty often results in effective 
resolution of PJI, it is not a successful outcome for the affected patients.  
The true numbers of incidence and final outcomes of PJI treatment are difficult to establish and 
represent a difficult challenge. A structured follow-up of patients and registers with both good 
coverage as well as completeness are needed64,65. 
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1.2.2 Air quality in surgical environment 
 
Orthopaedic joint implant surgery is regarded as one of the most infection sensitive procedures. 
Modern ventilation systems are needed to achieve good air quality through dilution and dispersion of 
bacteria carrying particles in the operating room66. Improvement of existing ventilation systems, 
through reconstruction or installation of new or additional components is often a significant 
investment. It can often be impossible to implement in older buildings, even without the economic 
limitations. Additional mobile laminar airflow (LAF) units can help to improvement of current 
ventilation systems67. However, in our department, their use was perceived to have a negative 
influence on the surgical working environment. 
Better clothing systems may also help to increase the air quality. There are requirements for clothing 
systems as the European Standard EN 13795 of the so-called Clean Air Suit (CAS)68 and 
manufacturers test their systems in standardised settings for certification purposes. This assessment is 
not always possible to confirm in real life settings and therefor we have to rely on certifications. 
Measurements carried out during movements in closed dispersal chambers69 can assess the source 
strength of CASs (individually emitted CFU/s). The high physical activity in these chambers produces 
higher values of CFU/s than observed in the surgical environment. There is no precise knowledge of 
an established association between the differences of measurements of garments with different density 
in the dispersal chambers and the differences in the real operative conditions70. Thus, standardised 
settings do not reflect the true CFU levels in surgical environments and the desired air quality is not 
always met71,72. Different numbers of operating personnel with diverse activities and special 
constellations (not infrequent at multidisciplinary centres) creates inevitably highly diverse and 
variable surgical environments. Moreover, heat generated by both staff and medical equipment 
generates powerful vortex patterns even in assumed predictable settings. Different reversed airflows 
can create inlet jets into the operating field, between the patient and personnel73. 
Counting of particles in the air can assess air quality but the correlation to microbiological load is 
poor. An established method to assess the quality of air is to measure the formation of living bacteria 
colonies per cubic meter of air by counting CFU values74. This is done by a set amount of suction of 
air from the operating field through a filter, which is changed according to set time intervals. These 
filters are subsequently incubated in laboratory settings and the developed colonies of bacteria are 
counted to calculate CFU/m3 values. 
Current requirements of air quality in infection prone surgery are <5 CFU/m3 with simultaneous use 
of CAS75,76. As there is yet no scientific evidence for any safe maximal values, we have to aim for 
even lower counts. The currently most common CASs in Sweden are reusable CASs made out of a 
mix of cotton and polyester fibres. Single-use suits made of polypropylene may generate lower 
CFU/m3 counts72 but create more waste and are therefor controversial in the aspect of the healthcare’s 
policy to reduce the negative impact it produces on our environment. 
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1.2.3 The patient insurance scheme in Sweden 
 
Patient insurance schemes can be grouped into two different systems, based on their legal background. 
The first scheme is negligence-based malpractice tort law and has three purposes: to discourage and 
prevent healthcare and individual physicians from practicing beyond their expertise, to punish the 
providers of low quality care and to compensate injured patients77. This scheme is internationally 
widespread and used in e.g. the United States and the United Kingdom. However malpractice tort law 
does not deliver to its expectations. Injuries are seldom persuaded and patients may need to file suits 
to learn whether negligence occurred78. Also it forces physicians to practice expensive defensive 
medicine79. The second scheme is non-tort and based on “avoidability” and preventability of patient 
injuries. This scheme has been practiced in Scandinavian countries for over 4 decades and Sweden 
pioneered the approach80. 
Everyone treated in the Swedish publicly financed healthcare system is insured against injury resulting 
from avoidable patient injuries. Public healthcare makes up approximately 96% of all provided 
healthcare in Sweden. In some areas, e.g. hip arthroplasties, this number reaches well above 99%. 
Infection-related injuries are compensable if the infectious agent was transmitted from an external 
source during the delivery of care and if the infection’s rarity and severity were unexpected as 
assessed from the patients’ past and current medical status. PJIs after hip arthroplasty surgery, 
resulting from intraoperative contamination (IC) and not from HS, are therefor considered as 
compensable injuries in Sweden. 
Patients´ claims are handled by the national patient insurance company Landstingens Ömsesidiga 
Försäkringsbolag81, founded in 1975 and co-owned by the Swedish 21 county councils (public 
healthcare). According to the Patient Injury Act all medical professions are covered by LÖF82, with 
increasing number of claims annually. LÖF handled 16000 claims in 2016 and almost one third of 
reimbursed claims were injuries related to orthopaedic procedures81. Moreover cemented THA is the 
procedure associated with highest numbers of claims83. According to conditions of insurance, six 
types of injuries are covered, resulting from: treatment injury, technical damage, inferior diagnostics, 
infection, patient accidents in care and injury related to incorrect application of medications. Patients 
report their injuries free of charge and this must be done within ten years. LÖF then obtains full 
medical records before review of claims by specialists with expertise within the concerned medical 
field. In case the event was not avoidable and no causative relation or inferiority between given 
treatment and outcome is observed, LÖF can reject a claim. If the opposite is observed, LÖF subtracts 
a lesser deductible and compensates for the prolonged recovery time or awards pay-outs for sustained 
permanent disability, in accordance with Insurance Sweden consensus tables84. 
The economic compensation is non-tort, reimbursing income loss, unreimbursed medical costs and a 
limited compensation for pain and suffering caused by the injury. It is also blame-free for practitioners 
and no records are shared with regulatory authorities. Therefore it is neither punitive damage 
compensation nor a sanctioning tool of healthcare providers but more precisely it supplements the 
extensive coverage offered by Swedish social and medical care systems. This can partly explain the 
lower compensations then in Anglo-American tort systems but simultaneously results in a simpler 
procedure for the claimants and with higher overall appeal success rates of 47% to 49.5% vs. 30% in 
the United States83,85. 
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1.2.4 Thromboembolic events and prophylaxis 
 
The most severe consequence of an acute VTE is sudden death, resulting from acute massive PE. 
Fortunately, postoperative fatal PE is a rare complication and often occurs in patients with other risk 
factors86. The long-term complications of VTE include recurrent VTE, postthrombotic syndrome and 
chronic thromboembolic pulmonary hypertension. The incidence of recurrence of VTE after first-
episode of DVT has been reported to be 24% within 5 years, with 20% of the recurrent VTE episodes 
being PEs87. The postthrombotic syndrome is a chronic condition characterised by oedema, pain, 
venous ectasis and severe cases painful leg ulcers88. The incidence rate is shown to be 4% to 6% 
within 7 years after a DVT following arthroplasty surgery of the hip or knee89. Finally, chronic 
thromboembolic pulmonary hypertension may occur after a single episode of PE and, if untreated, 
cause right heart failure90. The incidence within 2 years after an event of PE is 1% to 5%91. 
Elective primary hip and knee arthroplasties are common, standardised and widespread operations. 
Both of these major orthopaedic procedures carry a considerable risk of thrombosis and the most 
frequent medical complication of THA is VTE92. These operations have therefore become popular 
models for assessing TP treatments. Apart from studying outcomes of two different operations, the 
abundant studies describing the incidence of VTE focus mainly on two end-points, which results in a 
difficult comparison between studies. The first end-point is subclinical DVT assessed by routine 
venography or ultrasound examination regardless of symptoms. This method detects more events and 
may be regarded as a better measure of efficacy of treatment. However screening in trials may detect 
subclinical DVTs, raising the reported incidence and simultaneously preventing some from becoming 
symptomatic and detectable in clinical practice. The second end-point is the incidence of symptomatic 
DVTs, where the events are detected after a clinical suspicion. This approach resembles real clinical 
settings and focuses on the efficiency of TP drugs.  
Older randomised controlled trials show a symptomatic rate of VTE of 15% to 30% without 
prophylaxis93. Current studies report an incidence of symptomatic VTE within 90 days of surgery as 
0.7% to 1.8% in patients with postoperative TP94-98, including both DVT and PE. The use of TP is 
well established and recommended by several guidelines worldwide93,99,100 but without consensus 
regarding both length of treatment and the preferred therapeutic agent. 
The most commonly used TP medications after THA worldwide include ASA, fondaparinux, 
warfarin, LMWH and the recently introduced NOAC. NOACs have proved their efficiency as TP 
after THA in several clinical trials101-105. Besides their efficacy and efficiency, compared to LMWH, 
they offer reduced over-all costs due to oral administration106 and are often preferred by patients107. 
However concerns are raised regarding prolonged wound drainage108,109 and higher risk of 
bleeding110-112, but this is likewise contradicted by other studies113,114. 
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1.2.5 Swedish national quality and healthcare registers 
 
The unique Swedish personal identity number (PIN) facilitates linkage-studies between population 
and health data registers. It was introduced in 1947 and constitutes the basis of almost all aspects of 
everyday life, from direct assignment to new-borns, through schools, banks and employments, to all 
aspects of healthcare use. The consistency of its use is the reason behind the success of Swedish 
epidemiologic and socioeconomic research. 
Swedish National Patient Register (SNPR) was established in 1964 and is administrated by the 
governmental National Board of Health and Welfare. The register covers all (private and public) 
inpatient care since 1987 and outpatient care since 2001. The primary care is not covered. SNPR 
contains data in 4 different categories: patient related data (PIN, sex and place of residence –county, 
municipality, parish), caregivers’ data (assigned hospital and department number), administrative data 
(date and mode of admission and discharge, acute or elective care) and medical data (primary and 
secondary diagnosis, cause of injury or poisoning and procedures). The diagnoses and injuries are 
registered according to the 10th version of International Classification of Diseases (ICD) and SNPR 
does not register laterality. Currently over 99% of all hospital discharges and hospital based outpatient 
visits are registered and the PIN is found missing in only 2.9% of all discharges115. 
Swedish Prescribed Drug Register (SPDR) was initiated in 1999 and is also under the administration 
of National Board of Health and Welfare. In 2005 PIN was included in the register, which enabled 
matching of data with other registers. SPDR includes information on all prescribed outpatient drugs in 
Sweden, through automatic reporting by the pharmacies116. The following is reported for every 
individual prescription: PIN, date of prescription and expedition, name of the drug and its Anatomical 
Therapeutic Chemical (ATC) code, dose, prescribed quantity, instructions from the prescriber and 
prescriber details (profession and clinic).  
Swedish Hip Arthroplasty Register (SHAR) started in 1979117 as the second national quality register in 
Sweden. All orthopaedic units performing hip arthroplasties report to SHAR. The completeness of the 
register is reported as above 98%21. All primary operations and reoperations are to be reported to 
SHAR. It defines reoperation as any subsequent surgery in close relation to the already implanted 
prosthesis. Revisions are defined as a reoperation where parts or the entire prosthesis is exchanged or 
extracted. Registered data includes: PIN, age, sex, ICD-coded diagnosis, side, surgical approach, type 
of fixation, type of implant and cement, hospital, surgeon. Prosthesis survival is calculated by 
matching with the Swedish Death register. Finally, pre- and postoperative patient reported outcome 
measures are also registered.  
Statistics Sweden is a governmental agency responsible for producing national statistics through 
assignments from the government and other government agencies. The beginning of Statistics Sweden 
can be traced back to the church registration, imposed by the Church Law of 1686. The field of 
Statistics Sweden is diverse and extensive but in the content of this thesis, they supplied information 
from LISA (Longitudinal integration database for health insurance and labour market studies). 
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2 AIMS OF THE THESIS 
 
The aims of this thesis were to investigate the following aspects of hip arthroplasty: 
 
§ Analyse and compare the incidence, microbiology and outcome of PJI after hip arthroplasty due 
to degenerative disorder and fracture, including both primary and secondary fracture surgery. 
- Study I 
 
§ Evaluate the air quality with two new CAS systems through comparison with an existing and 
widely used CAS system, which was additionally complemented by two mobile LAF-units. 
- Study II 
 
§ Determine the proportion and outcome of patient claims which were filed to LÖF after PJIs 
and analyse any presence of socioeconomic, age and sex-linked differences among claimants. 
- Study III 
 
§ Compare LMWH and NOAC as TP after elective THA, through determination of effectiveness 
as incidence of VTE and assessment of safety by analysis of bleedings, reoperations and 
mortality. 
- Study IV 
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3 PATIENTS AND METHODS 
 
Studies I and II are based on outcomes of operations performed at the Department of Orthopaedics, 
Stockholm South General Hospital (Södersjukhuset). The hospital is owned by The Stockholm 
County Council but works in close collaboration with the medical university Karolinska Institutet. It 
offers healthcare to more than 2 million inhabitants of the County Council but is far from the only 
provider. Every year the hospital receives more than 160 000 emergency visits, holds over 600 beds, 
employs 4 600 co-workers and 6 000 operations are performed in the orthopaedic department. 
Studies III and IV cover the nationwide population of Sweden, a country of 10 millions inhabitants. 
These studies are mainly based on national quality and healthcare registers. 
 
3.1 STUDY I 
 
All patients operated between 1996 and 2005 were prospectively registered in a clinical audit 
database, where all complications (both early and late) were registered. During the study period a 
consecutive series of 1 155 HAs (406 uncemented unipolar HAs, 353 cemented unipolar HAs and 396 
cemented bipolar HAs) and 2 728 THAs (2 442 cemented THAs, 215 uncemented THAs and 71 
hybrids/reversed hybrids THAs) were identified in the registry and included in the study, in total 3 883 
hips. The indication for surgery was a degenerative or inflammatory hip disorder in 1 687 cases and 
hip fracture in 2 127 hips. Primary fracture prosthesis was performed in an acute displaced femoral 
neck fracture (Garden III and IV)118 and secondary fracture prosthesis due to fracture healing 
complications after internal fixation. After exclusion of patients operated due to malignancy, 
acetabular fractures and patients living abroad (therefore lost to follow-up), 3 807 arthroplasties 
remained and were included in the study. 
All patients received preoperative full body wash and prophylactic intravenous antibiotics and 
additional one or two doses of antibiotics postoperatively, according to guidelines at the time. For 
patients with either a registered PJI or a registered reoperation, individual patient records were 
searched until May 31, 2011, or death, in order to find information about all details regarding the PJI. 
Late PJIs and reoperations from our own department were crosschecked against SHAR (no additional 
cases were found) and SNPR (two additional cases), to find patients who had been reoperated or 
treated elsewhere in Sweden for a PJI up to December 31, 2010. 
 
   14 
Microbiology 
Microbiological records were requested from the laboratories involved and data about the type of 
sampling material and culture results were registered. Independent reviewers analysed the culture 
results and decided the final causative bacterial agent(s). An etiological agent was defined according 
to following criteria:  
1. Superficial or deep wound culture with staphylococcus aureus. 
2. Superficial or deep wound culture with monoculture of beta-haemolytic streptococci.  
3. Periprosthetic biopsies with the same bacterial finding in at least 50 % of the samples, minimum 
three biopsies.  
4. Three independent cultures of either perioperative deep swab or perioperative tissue samples, 
with the same bacterial agent.   
5. Positive blood culture in combination with skeletal changes, evident on X-ray or at surgery, and 
symptoms from this region.  
The criteria were set according to the present recommendations from the Infectious Diseases Society 
of Sweden. If more than one pathogen matched the criteria, we made no judgement as to which 
pathogen being more virulent and therefore likely to have caused the infection. The material from 
which the microbiological diagnosis was made was also registered. In the case that the bacterium was 
present in more than one type of culture, the culture material considered to have the trustworthiest 
significance was registered. Biopsy findings were considered more significant than synovial fluid, 
which was considered more reliable than blood culture findings, which was considered more 
significant than wound cultures. If more than one bacterium matched the criteria the infection was 
defined as polymicrobial and these are presented separately.  
All infections were classified into 3 types depending on the time to first symptoms of an infection. We 
used the criteria set up by the Swedish Association of Infectious Diseases119 and by Zimmerli and 
Ochsner59; Infections with symptom onset within 3 months were defined as early, infections with 
symptom onset between 3 months and 2 years were defined as delayed and infections with symptom 
onset at 2 years or more were defined late.  
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3.2 STUDY II 
 
All operations in this study were performed in 2013. The surgical procedures included in the study 
(elective total arthroplasties of hips and knees) were all performed in standardised setting, in the same 
OR, equipped with turbulent ventilation, HEPA-filter and air-intake of 620L/s. The procedures 
included cemented, uncemented and hybrid implants, all performed by experienced orthopaedic 
surgeons with one junior assistant. In total there were between 6 to 9 staff present at each operation, 
including both the operating personnel, as well as the passive observers responsible for data collection. 
We had strict door control with only one opening throughout all of the operations. 
Three clothing systems were studied prospectively, all supplied as brand-new. There were 13 
operations performed in, at that time currently used, reusable mixed material Mertex P-3477, Textilia 
AB (69% cotton, 30% polyester and 1% carbon fibre) accompanied by two mobile LAF units (TOUL, 
Meditech AB, Västerås, Sweden) with a joint airflow of 220 L/min. In 13 operations reusable Olefin, 
Textilia AB (woven polypropylene/polyethene material) was used, without any TOUL-device. The 
third clothing system, single-use BARRIER® Clean Air Suit, Mölnlycke Health Care (non-woven, 
spunbonded polypropylene), was used to perform 11 procedures, also without any TOUL-device. 
Both the Mertex P-3477 dress and the BARRIER® Clean Air Suit, have cuffs at the bottom of the long 
legged pants and the short-sleeved shirts (at the arms, bottom and neckline). Olefin dresses had no 
cuffs at the bottom of the shirts and were therefore worn inside the pants. The clothing systems were 
evenly distributed between morning and afternoon operations. During each operation, all staff present 
in the OR wore the same kind of clothing system and changed garments before next procedure. 
 
Air quality measurements 
Measurements were all performed by the same, experienced OR nurse, not involved in the surgical 
procedure. Air sampling was done with Sartorius Air Sampler MD8® (Sartorius AG, Goettingen, 
Germany). There are no international standards of air sampling but the Sartorious device is a long-
established method120 and recommended by the Swedish Standards Institute75. Air was sucked through 
a sterile tube with standardised airflow of 100L/min over a gelatine filter, placed 35 - 50 cm from the 
operating field. Special care was taken to avoid any splashes of fluids from the operating area71. It was 
changed every 10 minutes, with six or seven measurements per operation. The 10-minute interval is 
the recommended time, as longer sampling times may decrease the bacterial counts through 
dehydration75. Each filter was placed, immediately after removal, on a sterile blood agar plate and sent 
(on the same day) to the laboratory of Clinical Microbiology at the Karolinska University Hospital in 
Huddinge. The plates were incubated for two days at 35OC and the amount of colonies were then 
counted and expressed as CFU/m3. Samples with condensate on the lid of the agar plate, macroscopic 
fluid or touch contamination, and damaged filters were excluded from analysis. Operations with over 
50% excluded samples were subsequently dropped from the analysis. 
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3.3 STUDY III 
 
This study is based on a previously described population55 with regard to the national incidence of PJI 
after primary THA in Sweden. All patients who had undergone a primary THA, between 1st of July 
2005 and 31st of December 2008, were initially retrieved from SHAR and matched with the SPDR for 
continuous outpatient antibiotic medication for at least four weeks after surgery. The observation time 
was set to two years postoperatively, to include only early and delayed PJIs59. This protocol allowed 
for inclusion of the compensable PJIs, since IC occurs within the first 2 years. Simultaneously the late 
appearing PJIs caused by HS were excluded. No additional selection was made to exclude any 
possible HS infections within the first two postoperative years. Antibiotic treatments with indications 
other then PJI were excluded. A questionnaire for each of the identified patients was sent to the 
operating units. This verified treatment for PJI and the case-specific diagnostic criteria of PJI, 
according to the definition by the Workgroup of the Musculoskeletal Infection Society121. 99% of all 
questionnaires were returned, resulting in a final number of 443 treated PJIs. 
We identified 441 patients with PJIs in the LISA database. This enabled matching on highest achieved 
level of education as a socioeconomic factor, which was combined into four levels; elementary school, 
high school, post graduate and unknown. For each patient, we also recorded gender, performing 
hospital, age at primary THA operation and the indication for surgery. Primary osteoarthritis and hip 
fracture are the two most common indications, with apparent different patient characteristics. 
Consequently we wanted to present these two groups separately in our analysis. All other indications 
were merged together into a third group, called other. To examine any national differences, each 
operating unit was classified according to its location by provision of care (the 21 Swedish counties) 
and separately by order: university hospital, referral county hospital, local hospital and private. 
 
Patient claims 
Finally we compared all PJIs with LÖF’s database in November 2016 for patient claims and outcome 
of claims review. The timeframe was regarded as sufficient for both patients to file claims after 
delayed infections in case of complicated and prolonged PJI treatment and also for LÖF to review and 
conclude their decision. Filed patient claims were recorded and their decisions were grouped into six 
outcomes: rejected claims, approved prolonged recovery (grouped as prolonged by less or more than 3 
months) and approved acquired permanent disability (classified as levels of 1% to 15%, 16% to 30% 
and above 30%). 
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3.4 STUDY IV 
 
This study is based on a previously cross-linked register database, initiated by SHAR122 and 78 066 
primary THAs, operated between years 2008 and 2012, were extracted. In bilaterally patients operated 
(n= 7 105) only the first hip was included. This allowed for better tracing of prescriptions and 
complications, as well as exclusion of possible additive effect of a second operation. Patients with 
other diagnoses than primary osteoarthritis (n= 12 186) were excluded. Using ICD-coding from 
SNPR, we additionally excluded subjects with VTE, up to five years before operation (n= 1 121), to 
limit any effect of previous conditions on outcome. To reduce bias from on-going or recent potent 
antithrombotic agents at time of surgery, we excluded patients who had been prescribed Warfarin, 
LMWH and NOAC, up to six months prior to the THA (n= 4 971). This was done using data recorded 
in SPDR. From SPDR we also collected data on postoperative prescribed and purchased TP 
medication. Patients with no data on purchase of postoperative TP treatment (n= 16 899) were 
excluded. A subanalysis revealed that most patients purchased the prescribed TP medications on the 
third to fifth day after the index operation. We decided that setting a cut-off of purchase within 10 
postoperative days, will limit the inclusion of high-risk patients by exclusion of those who, possibly 
due to comorbidities, required longer hospital care (n= 3 151). 32 663 patients operated with a THA 
were included in this study (Figure 1).  
We recorded sex, age at operation, body mass index 
(BMI), American Society of Anaesthesiologists 
score (ASA-score), Elixhauser score, purchase of 
platelet aggregation inhibitor (within 6 months 
before operation) and type of implant fixation for 
each patient. Duration of TP was calculated as the 
sum of postoperative hospital days and the amount 
of prescribed daily doses. TP was defined as short, if 
the patients had received treatment for less than 28 
days. Consequently TP of 28 days or longer was 
classified as extended. The data from LISA provided 
both the patients´ highest achieved level of 
education and their civil state at the time of 
operation. 
We divided the TP medications into two groups, 
LMWH and NOAC. In the LMWH group we 
included three medications by their corresponding 
Anatomical Therapeutic Chemical (ATC) codes: 
dalteparin, enoxaparin and tinzaparin. The regimen 
was one daily subcutaneous dose of 5000, 4000 and 
4500 IU respectively. The NOAC group consisted 
of dabigatran (twice-daily oral dose of 110mg) and 
rivaroxaban (one daily oral dose of 10mg oral dose). 
A list of all antithrombotic agents and their 
categorization is presented in Table 1. 
Figure 1 
Study flowchart of patient selection 
Patients with primary osteoarthritis 
n = 58 775 
Bilateral THAs 
- second hip excluded 
n = 7 105 
Other diagnoses than 
primary osteoarthritis 
n = 12 186 
VTE (ICD-10) within 
5 years before operation 
n = 1 121 
Purchased Warfarin within 
6 months before operation 
n = 2 510 
Purchased LMWH or NOAC 
within 6 months before operation 
n = 2 461 
No registered postoperative 
VTE medication 
n = 16 899 
No purchase of prescription 
within 10 days of the operation 
n = 3 151 
Patients with primary osteoarthritis 
n = 32 633 
All THA procedures 
registered in SHAR 2008 - 2012 
n = 78 066 
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The occurrence of all events was studied up to 90 days postoperatively. This timeline was based on 
previous findings of time course of thromboembolic events after joint replacement surgery95,96,123. Our 
primary effectiveness outcomes of VTE, DVT and PE, were analysed through SNPR by the 
corresponding ICD-codes. The secondary safety outcomes of bleedings were also extracted from 
SNPR. Due to absence of recognized standards of reporting bleeding complications in register studies, 
a deliberately wide-ranging, catchall definition was chosen. No distinction was made between major 
and minor bleedings and every code resulting in inclusion of possible bleeding complication was 
included. Both reoperations (any open surgical intervention following THA) and mortality within 90 
days of the index operation were collected from SHAR. A complete list of the ICD-codes for 
diagnostic outcomes is presented in Table 2. 
Table 1 
List of antithrombotic agents, grouped and categorized by study's variable type 
 
GROUP NAME ATC-CODE* VARIABLE 
excluding** studied confounding 
Vitamin K antagonists Warfarin B01AA03 X     
Heparin group Dalteparin B01AB04 X X  
 Enoxaparin B01AB05 X X  
 Tinzaparin B01AB10 X X   
Platelet aggregation  Clopidogrel B01AC04   X 
inhibitors  Acetylsalicylic acid B01AC06   X 
excluding heparin Dipyridamole B01AC07   X 
 Epoprostenol B01AC09   X 
 Iloprost B01AC11   X 
 Abciximab B01AC13   X 
 Eptifibatide B01AC16   X 
 Tirofiban B01AC17   X 
 Treprostinil B01AC21   X 
 Prasugrel B01AC22   X 
 Ticagrelor B01AC24   X 
 Combination agents B01AC30   X 
Direct trombin inhibitors Dabigatran etexilate B01AE07 X X   
Direct factor Xa inhibitors Rivaroxaban B01AF01 X X   
* = Anatomical Therapeutic Chemical Code 
** = Excluded patients from the final cohort if prescribed within 6 months preoperatively 
 
Table 2 
ICD-10 codes of studied outcomes, grouped by the study's endpoints: 
primary (effectiveness) and secondary (safety). 
 EFFECTIVENESS SAFETY* 
VTE DVT PE Identified bleedings No identified bleedings 
I82.8 I81.9 I26.0 D62.9 K22.6 M25.4G S06.5 H35.6A I60.7 K25.2 L60.8J N42.1 N95.0X T79.6 
I82.2 I82.9 I26.9 H11.3 K25.0 M25.4H S06.50 H35.6B I61.0 K25.6 M25.4 N50.1A R04.1 T81.1 
I82.3 I82.8  H35.6 K25.4 N02.4 S06.6 H35.6C I61.1 K26.4 M25.4B N50.1B R04.8 T84.8X 
I26.0 I82.2  H43.1 K26.0 N02.9 T140A H35.6W I61.2 K26.6 M25.4C N89.7 R19.8A T85.6 
I26.9 I82.3  I60.0 K26.2 N92.4 T81.0 H35.6X I61.3 K27.0 M25.4D N83.6 R23.3  
I81.9   I60.8 K29.0 N95.0 T84.8 H45.0 I61.5 K27.2 M62.2 N83.7 R23.3A  
I82.9   I60.9 K55.0 N95.0A T84.8F H92.2 I61.6 K27.4 N02.0 N85.7 R23.3B  
   I61.4 K62.5 N95.0B T84.9 I31.2 I62.1 K27.6 N02.1 N89.7 R23.3C  
   I61.8 K62.6 R04.0 T85.8 I60.1 I62.9 K28.0 N02.2 N92.2 R23.3W  
   I61.9 K92.0 R04.2 T85.9 I60.2 I69.2 K28.2 N02.3 N92.3 S06.40  
   I62.0 K92.1 R04.9 T88.7 I60.3 I85.0 K28.4 N02.5 N93.0 S06.41  
   I64.9 K92.2 R31.9 T88.7X I60.4 I98.3 K28.6 N02.6 N93.8 S06.51  
   I69.0 M25.0 R58.9 T88.8 I60.5 J38.3J K66.1 N02.7 N93.9 S06.60  
   I69.1 M25.4F S06.4 T88.9 I60.6 K05.0 K76.2 N02.8 N95.0W S06.61  
* = Presented with distinction between codes that did and did not confirm bleedings  
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3.5 STATISTICAL ANALYSES 
 
Study I 
The Mann-Whitney U-test was used for scale variables in independent groups. Nominal variables 
were tested with the Fisher’s exact test. Cox regression analysis was used to evaluate factors 
associated with a PJI. Age, sex, indication for surgery, microbiological finding and type of prosthesis 
was tested as independent variables in the model. First, crude associations for each factor were studied 
in univariable models. Secondly, a multivariable model with all independent factors was used to study 
the adjusted associations. The associations are presented as hazard ratios (HRs) with 95% confidence 
intervals (CIs). All tests were two-sided and the level of significance was set to p < 0.05. We used 
IBM SPSS Statistics software (ver. 21). 
 
Study II 
We calculated the median and mean values of CFU for each operation as well as each clothing system. 
The Olefin clothing and the BARRIER® Clean Air Suit were then independently compared to our 
existing TOUL-assisted Mertex P-3477 garment. As outliers and non-standard distribution was 
observed in all three clean air suits, the comparison was based on median values, using the Mann-
Whitney U-test. We used IBM SPSS Statistics software (ver. 21). 
 
Study III 
The Mann–Whitney U test was used for scale variables in independent groups and the Pearson Chi-
Square test was used for nominal variables. Subsequently logistic regression analysis was performed 
on patients’ characteristics to evaluate factors associated with insurance claim. We analysed both a 
univariate and multivariate model. Associations are presented as odds ratios (ORs) with 95% 
confidence intervals (CIs). We used IBM SPSS Statistics software (ver. 23). 
 
Study IV 
The statistical analysis was performed using R, version 3.4.2. The data was analysed in a binary 
logistic regression model to determine the odds ratio (OR) with a 95% confidence interval (CI). A p-
value below 0.05 was considered statistically significant. Each of the observed outcomes was used as 
the dependent variable in the regression analysis. We calculated the OR both in a univariate 
(unadjusted) and a multivariate analysis, adjusted for length of TP, sex, age and previous treatment 
with platelet aggregation inhibitors as confounders. 
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3.6 ETHICS 
 
All studies were conducted according to the World Medical Association’s Declaration of Helsinki and 
approved before initiation by the regional ethical review boards: 
 
Study I 
The Regional Ethical Review Board at the Karolinska Institutet, Stockholm 
(ref no 2013/1190-31/1) 
 
Study II 
The Regional Ethical Review Board at the Karolinska Institutet, Stockholm 
(ref no 2013/246-31/4) 
 
Study III 
The Regional Ethical Review Board at the University of Gothenburg 
(ref no 622-16) 
 
Study IV 
The Regional Ethical Review Board at the University of Gothenburg 
(ref no 271-14) 
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4 RESULTS 
 
4.1 STUDY I 
 
We identified 62 of 3 807 (1.6%) hips reoperated due to a PJI. There were seven (0.4%) SSIs in 
patients operated for degenerative hip disorder; 47 (2.2%) were found in patients operated with 
fracture prosthesis: 22 from the primary (2.0%) and 25 from the secondary (2.5%) fracture prosthesis 
group, respectively. HS infections dominated with six hips in the degenerative hip disorder group 
compared with two in the primary fracture prosthesis group. 
Microbiological cultures showed a dominance of staphylococcus aureus and coagulase-negative 
staphylococci in the fracture group, whereas there was a trend to more polybacterial infections in 
patients with degenerative hip disorder. Baseline and infection data for all patients is presented in 
Table 3. 
Finally a multivariate Cox regression analysis was performed to analyse factors associated with a 
significantly increased risk for developing a surgical-site PJI. We adjusted for age, gender, surgeon 
experience, prosthesis type and indication for prosthesis as independent factors in. The only factors 
with significant association were both fracture indication for surgery, primary (HR 4.3) and secondary 
(HR 6.1) fracture prosthesis, and male gender (HR 2.0). The analysis is presented in Table 4. 
When examining the treatment outcome of PJIs, we found that 25 (10%) patients were treated with 
open debridement and had the prosthesis preserved, 10 (16%) patients underwent a two-stage revision 
with exchange of prosthesis components and the treatment of 27 (44%) patients resulted in permanent 
resection arthroplasty. In 11 patients this was performed as part of the primary treatment plan and 16 
resections were the result of treatment failure.  22 (81%) of resection arthroplasties were performed in 
fracture patients. 
Life-long antibiotic therapy was required for 10 patients; in four after their resection procedure and in 
six patients in the prosthesis-preserving group. None in the two-stage revision group needed life-long 
antibiotic treatment. Finally 6 patients (10%) died during the treatment for infection, 5 of which were 
in the hip-fracture group. 
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Table 3 
Baseline and infection data for all patients included in relation to the indication for surgery 
 
 All 
(n= 3807) 
Degenerative 
hip prosthesis 
(n= 1682) 
Primary fracture 
prosthesis 
(n= 1122) 
Secondary fracture 
prosthesis 
(n= 1003) 
p-value 
BASELINE      
      Age mean (SD) 75.7 (12.1) 69.3 (12.1) 82.1 (8.1) 81.3 (10.7) <0.001 
Gender –n (%)       
Female 2755 (72) 1098 (65) 873 (78) 784 (78)  
Male 1052 (28) 584 (35) 249 (22) 219 (22) <0.001 
Type of prosthesis –n (%)      
THA 2656 (70) 1681 (100) 348 (31) 627 (63)  
Cemented HA 745 (20) 0 (0) 583 (52) 162 (16)  
Uncemented HA 406 (11) 1 (0) 191 (17) 214 (21) <0.001 
Surgeon’s experience –n (%)      
Registrar 751 (20) 390 (23) 208 (19) 153 (15)  
Postregistrar 3056 (80) 1292 (77) 914 (81) 850 (85) <0.001 
INFECTIONS –n (%) 62 (1.6) 13 (0.8) 24 (2.1) 25 (2.5)  
      Symptom onset –n (%)     
 Early 47 (76) 7 (54) 19 (79) 21 (84) 
Delayed  6 (10) 1 (8) 2 (8) 3 (12) 
Late  9 (14) 5 (38) 3 (13) 1 (4) 0.08 
Type of infection –n (%)      
Surgical site  54 (87) 7 (54) 22 (92) 25 (100)  
Haematogenic 8 (13) 6 (46) 2 (8) 0 (0) <0.001 
Bacterial specimen* –n (%)      
Staph. aureus  30 (56) 5 (38) 12 (67) 13 (56)  
CoNS 7 (13) 1 (8) 1 (6) 5 (22)  
G- + Poly 13 (24) 6 (46) 5 (28) 2 (9)  
Others 4 (7) 1 (8) 0 (0) 3 (13) 0.09 
THA= total hip arthroplasty, HA= hemiarthroplasty, CoNS: coagulas-negative staphylococci, 
G- + Poly= Gram negative infections and polymicrobial infections, Others= streptococci, peptostreptococci 
*8 cases without defined bacterial specimen, all fracture prosthesis, primary (6 cases) and secondary (2 cases) 
 
Table 4 
Reoperation rate for patients with surgical site infections and multivariable Cox regression adjusting for:  
age, gender, surgeon’s experience, type of prosthesis and indication for surgery 
 
 Reoperation rate n (%) Multivariable Cox regression 
 (total n= 54) HR (95% CI) p-value 
Age group    
< 75 years (n=1504) 16 (1.1) 1 (reference)  
≥75 years (n=2303) 38 (1.7) 0.9 (0.5-1.7) 0.7 
Gender    
Female (n=2755) 34 (1.2) 1 (reference)  
Male (n=1052) 20 (1.9) 2.0 (1.2-3.6) 0.01 
Surgeon’s experience    
Registrar (n=751) 7 (0.9) 1 (reference)  
Post registrar (n=3056) 47 (1.5) 1.5 (0.7-3.3) 0.3 
Type of prosthesis    
THA (n=2656) 26 (1.0) 1 (reference)  
Cemented HA (n=745) 18 (2.4) 1.7 (0.8-3.5) 0.2 
Uncemented HA (n=406) 10 (2.5) 1.8 (0.8-3.9) 0.2 
Indication      
Degenerative hip disorder (n=1682) 7 (0.4) 1 (reference)  
Primary fracture prosthesis (n=1122) 22 (2.0) 4.3 (1.6-11.7) 0.004 
Secondary fracture prosthesis (n=1003) 25 (2.5) 6.1 (2.5-15.1) <0.001 
THA= total hip arthroplasty, HR= hazard ratio, HA= hemiarthroplasty, CI= confidence interval  
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4.2 STUDY II 
 
Out of the total 244 measurements, we had to exclude 37 (15%). This was done due to the condensate 
on the lids of the agar plates (25 measurements), macroscopic fluid splash contaminations (7 
measurements), damaged filters (4 measurements) and one tactile contamination. In three operations 
with the Olefin clothing, more than half of the measurements were excluded. Therefore, these three 
procedures were not regarded as representable and were consequently eliminated from the analysis. 
Conclusively we analysed 201 measurement, 78 of which with the TOUL-assisted Mertex system, 52 
with the Olefin clothing and 65 measurements with the BARRIER® Clean Air Suit. 
We had one door opening, with BARRIER® Clean Air Suit, which did not show any evident rise in 
measured CFU-values. 
Our main finding was the significantly lowest median CFU/m3 of the BARRIER® Clean Air Suit. The 
median values of the studied clothing systems were 20.0 CFU/m3 for the TOUL-assisted Mertex 
system, 22.5 CFU/m3 for the Olefin system and 12 CFU/m3 for the BARRIER® Clean Air Suit. The 
results are summarised in Table 5. We observed a wide spread of measurements between the different 
clothing systems, as well as between individual operations within the same clothing systems. The 
noticeably higher mean values (27.9 CFU/m3 of the TOUL-assisted Mertex system, 38.8 CFU/m3 of 
the Olefin clothing and 22.8 CFU/m3 of the BARRIER® Clean Air Suit) reflect the impact of the 
outliers, present in every clothing system. The reason of the high outlying values could not be traced 
back or explained by a specific date of surgery, temporary failure of ventilation or sterile processing 
department, malfunctioning Clean Air Suit items, nor by the surgical teams or specific individuals. 
 
 
 
 
 
Table 5 
Comparison of all included operations and measurements of the three clothing systems 
 
Clothing system 
Operations Measurements CFU/m3  
total n= 37 total n= 207 Median Mean Min - Max p-value 
Mertex P-3477 + two TOUL devices 13 78 20.0 27.9 1-148 1 (reference) 
Olefin clothing 10 52 22.5 38.8 0-228 0.622 
BARRIER® Clean Air Suit 11 65 12.0 22.8 0-280 0.009 
CFU/m3 = Colony Forming Units per cubic meter 
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4.3 STUDY III 
 
We identified that 329 (75%) of the total 441 patients with PJIs did not file a claim of injury to LÖF. 
Of those 112 that did, 108 (96%) were accepted as eligible for compensation. Table 6 summarizes 
patients’ baseline data and claim rates. Patients’ age above the median of 72 years (OR= 0.4,  
CI 0,3 - 0.7, p= 0.001) and fracture diagnosis (OR= 0.4, CI 0.2 - 0.9, p= 0.02) were the only 
significant factors associated with not filing a claim of injury in a univariate logistic regression model. 
When adjusted for age, gender, diagnosis and level of education in the later multivariate model, they 
remained significant, with identical OR, CI and p-values. The analysis is presented in Table 7. 
The variation in claims between counties ranged between 50% (1 of 2 PJIs) and none (of 3 PJIs). Both 
were identified in smaller counties. Only two counties, Västra Götaland (Gothenburg) and Stockholm, 
had more then 10 claimants (26 with 38% claim rate and 23 with 30% claim rate respectively). We 
could not observe any national differences in claims above the county level. Patients from smaller 
hospitals filed claims more often, with the highest rates from the private hospitals (34%) and lowest 
from university hospitals (16%) (p= 0.059). We could not observe any correlating trends to higher or 
lower age of patients between claim rates and types of hospitals; university (𝑥= 68.2, SD 14.7), county 
(𝑥= 71.5, SD 10.7), local (𝑥= 70.1, SD 9.6) and private (𝑥= 69.7, SD 11.5). Private hospitals operated 
only patients with osteoarthritis, with only one patient with other diagnosis (femoral head necrosis).  
Analysis of LÖFs claim decisions, as visualized in Figure 2, reveals that 44 (39%) claimants were 
compensated for prolonged recovery time and 64 (57%) for permanent disability, due to PJI. There 
was an equal distribution of age groups within the three largest decision groups; recovery <3 months 
(𝑥= 66.2, SD 12.0) recovery >3 months (𝑥= 68.3 SD 8.7) and disability 1-15% (𝑥= 67.0, SD 11.1). 
 
Table 6     
Baseline data for all patients included in relation to claim of injury at LÖF. 
 
 All No claim Claim 
p-value 
  (n= 441) (n= 329, 75%) (n= 112, 25%) 
Age (%)     Mean (SD*) 70,7 (11) 71,8 (11) 67,4 (10) <0,001 
Distribution (%)     
<50 15 (3) 10 (67) 5 (33)  
51-60 66 (15) 45 (68) 21 (32)  
61-70 116 (26) 78 (67) 38 (33)  
71-80 167 (38) 126 (76) 41 (25)  
>80 77 (18) 70 (91) 7 (9) 0,003 
Gender (%)     
Female 222 (50) 158 (71) 64 (29)  
Male 219 (49) 171 (78) 48 (22) 0,096 
Diagnosis (%)     
Primary osteoarthritis 328 (74) 236 (72) 92 (28)  
Hip fracture 67 (15) 58 (87) 9 (13)  
Other 46 (10) 35 (76) 11 (24) 0,042 
Education (%)     
Elementary school 205 (47) 161 (79) 44 (22)  
High school 167 (38) 119 (71) 48 (29)  
Post graduate 66 (15) 46 (79) 20 (30) 0,176 
Unknown 3 (1) 3 (100) 0 (0)  
Hospitals (%)     
University 55 (13) 46 (84) 9 (16)  
County 203 (46) 158 (78) 45 (22)  
Local 151 (34) 104 (69) 47 (31)  
Private 32 (7) 21 (66) 11 (34) 0,059 
* SD =Standard deviation 
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Table 7 
      Logistic regression to evaluate factors associated with insurance claim. 
       
 All Claim made Univariable Multivariable 
  n n (%) OR* (95%CI) p-value OR* (95%CI) p-value 
Age       
<73 years 224 74 (33) 1 (reference)  1 (reference)  
≥ 73 years 217 38 (18) 0.4 (0.3-0.7) <0.001 0.4 (0.3-0.7) <0.001 
Gender       
Male 219 48 (22) 1 (reference)    
Female 222 64 (29) 1.4 (0.9-2.2) 0.1     
Diagnosis       
Primary osteoarthritis 336 92 (27) 1 (reference)  1 (reference)  
Hip fracture 67 9 (13) 0.4 (0.2-0.9) 0.02 0.4 (0.2-0.9) 0.02 
Other 38 11 (29) 1.1 (0.5-2.3) 0.8 0.9 (0.4-2.0) 0.8 
Level of education       
Elementary school 205 44 (22) 1 (reference)    
Secondary school 168 48 (29) 1.5 (0.9-2.3) 0.1   
University 65 20 (31) 1.6 (0.9-3.0) 0.1     
* OR= odds ratio        
 
 
 
	Figure 2 
LÖF’s claims grouped by decisions (n and % of total) with distribution of age groups within: 
rejected claims, recoveries prolonged shorter and longer than 3 months and % of acquired permanent disability 
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4.4 STUDY IV 
 
In the cohort of 32 663 THAs, we identified 5 752 (18%) patients with NOAC and 26 881 (82%) with 
LMWH TP treatment. Table 8 summarizes patients’ characteristics and clinical properties of the two 
groups. The two depictions of comorbidities diverge as more NOAC patients belong to lower classes 
of ASA-score but reveal a 21% higher mean Elixhauser score. The achieved level of education was 
lower in individuals with NOAC treatment and they were also more frequently operated with 
cemented fixation. As dabigatran and rivaroxaban were approved for postoperative TP in 2008 in 
Europe, the NOACs prescription in the study’s two initial years was low, but increased to a steady 
25% share during the last three studied years. 
Our primary finding was a significantly lower risk of VTE in the NOAC group (incidence 0.4%), 
compared to the LMWH group (incidence 1.0%), with adjusted OR= 0.42 (CI 0.26 - 0.67), as 
presented in Table 9. DVT was observed in 17 (0.3%) patients with NOAC treatment and 170 (0.6%) 
patients with LMWH, adjusted OR= 0.52 (CI 0.29 - 0.90). Consecutively 8 (0.1%) individuals in the 
NOAC group suffered PE vs. 108 (0.4%) in the LMWH group, adjusted OR= 0.32 (CI 0.14 - 0.67). In 
comparison with LMWH, NOAC did not present any significant difference in risk of the safety 
outcomes of bleedings, reoperations or mortality. 
Majority (84%) of NOAC patients were prescribed extended TP, while LMWH was predominantly 
(83%) used as short TP. The distribution of TP duration is presented in Table 10 and visualized in 
Figure 3. The limited number of patients receiving short TP with NOAC did not allow for analysis of 
short versus extended prophylaxis in this group. However, adjusting for duration of TP in the subset of 
patients treated with LMWH did not show any significant difference with regards the incidence of 
VTE (OR= 0.95, CI 0.67 - 1.31). 
Table 8 
Baseline data for all included patients, grouped by thromboprophylactic regimen 
  NOAC LMWH p-value 
 n=5752 n=26881 
SEX= female -n (%) 3329 (57.9) 15339 (57.1) 0.264 
AGE -mean (SD) 68.19 (9.97) 67.75 (9.95) 0.002 
BMI (kg/m2) -mean (SD*) 27.45 (4.45) 27.28 (5.29) 0.031 
PROPHYLAXIS= extended duration -n (%) 4849 (84.3) 4461 (16.6) <0.001 
ASA -n (%)    
Healthy (I) 1605 (29.2) 6926 (26.5)  
Mild (II) 3280 (59.7) 15913 (60.9)  
Severe (III) 598 (10.9) 3228 (12.3)  
Life-threatening (IV) 7 (0.1) 70 (0.3)  
Moribund (V) 0 (0.0) 1 (0.0) <0.001 
ELIXHAUSER -mean (SD*) 0.76 (0.93) 0.63 (0.93) <0.001 
EDUCATION -n (%)    
Low 1929 (33.6) 8616 (32.1)  
Middle 2447 (42.6) 11113 (41.4)  
High 1372 (23.9) 7120 (26.5) <0.001 
CIVIL STATE -n (%)    
Couple 3260 (56.7) 15254 (56.8)  
Single 1622 (28.2) 7774 (29.0)  
Widow 866 (15.1) 3822 (14.2) 0.205 
FIXATION -n (%)    
Cemented 4142 (72.1) 17123 (64.0)  
Uncemented 888 (15.5) 4371 (16.3)  
Hybrid 93 (1.6) 210 (0.8)  
Reversed hybrid 609 (10.6) 4607 (17.2)  
Resurfacing 13 (0.2) 463 (1.7) <0.001 
*SD= Standard deviation 
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Table 9 
Thromboprophylactic regimen with outcome and logistic regression, both crude and adjusting for 
age, sex, length of thromboprophylaxis and previous treatment with platelet aggregation inhibitors 
 
Outcome Prophylaxis 
Complication Odds Ratio (95% CI) 
n (%) Unadjusted* Adjusted* 
VTE LMWH 264 (1.0) 0.42 (0.27-0.63) 0.42 (0.26-0.67) NOAC 24 (0.4) 
DVT 
LMWH 170 (0.6) 
0.47 (0.27-0.74) 0.52 (0.29-0.90) 
NOAC 17 (0.3) 
PE 
LMWH 108 (0.4) 
0.35 (0.15-0.66) 0.32 (0.14-0.67) 
NOAC 8 (0.1) 
Bleeding LMWH 468 (1.7) 1.00 (1.00-1.00) 0.99 (1.00-1.00) 
NOAC 102 (1.8) 
Reoperation 
LMWH 162 (0.6) 
1.13 (0.78-1.58) 0.99 (0.64-1.51) 
NOAC 39 (0.7) 
Mortality LMWH 38 (0.1) 0.74 (0.28-1.62) 0.84 (0.28-2.25) 
NOAC 6 (0.1) 
* = with LMWH as 1 (reference)  
CI -Confidence Interval, VTE -Venous Thromboembolism, DVT -Deep Venous Thrombosis, LE -Pulmonary Embolism 
 
Table 10 
Duration of prophylaxis with distribution of therapeutic agents within groups 
 
Agent Duration of prophylaxis Total 
Short Extended 
LMWH (%)  22420 (83) 4461 (17) 26881 
 Dalteparin (%) 13979 (76) 4458 (24) 18437 
 Enoxaparin (%) 3128 (100) 0 (0) 3128 
 Tinzaparin (%) 5313 (100) 3 (0) 5316 
NOAC (%)  903 (16) 4849 (84) 5752 
 Dabigatran (%) 726 (19) 3189 (81) 3915 
 Rivaroxaban (%) 177 (10) 1660 (90) 1837 
Total (%) 23320 (71) 9310 (29) 32633 
 
Figure 3 
Distribution of NOAK and LMWH according to duration of thromboprophylaxis in days 
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5 DISCUSSION 
 
The success of hip arthroplasties is reflected in the great and increasing numbers of operations 
performed each year. The improving implant survival offers surgical treatment to younger patients124, 
simultaneously as the increasing safety of operative techniques and perioperative care enables older 
patients and those with increased comorbidities to benefit from arthroplasties. Even though the 
complication rates are low, the absolute numbers of patients with complications are rising as the 
numbers of procedures increase. This represents both a great challenge and a call for continuous 
improvement. 
In this thesis aspects of two complications after hip arthroplasty are discussed. Both have gone from 
being relatively frequent complications of an uncommon procedure in the early days of hip 
arthroplasty to infrequent complications of a common procedure, resulting in many more suffering 
patients. Prosthetic joint infection (Study I - III) is the most feared complication and venous 
thromboembolism is the most common medical complication, VTE (Study IV). 
 
5.1 PROSTHETIC JOINT INFECTIONS 
 
5.1.1 Incidence and outcome 
 
PJI is a terrible complication and many parallels to other serious diseases, such as cancer, can be 
drawn125. The five-year mortality rate of patients with PJI is in some cases higher than of many 
cancers, up to 26% to 71%48,56. Also many patients do not survive treatment for PJI. In a cohort of 
patients operated between 1996 and 2009 a 7% mortality rate has been reported in two-stage 
regimen126 when, after the removal of the original implant, an antibiotic loaded cement spacer is 
implanted for subsequent second stage reimplantation of a new permanent arthroplasty. The results of 
Study I show a 10% mortality rate during treatment, before resolution of infection.  
Incidence rates of PJI after primary THA range between 0.2% and 1.6%51,55,127,128. The results from 
Study I with 0.4% SSIs after elective surgery for degenerative hip disorder corresponds to these 
previously reported findings. However the wide range of incidence reflects different follow-up times, 
populations, performing centres and diagnostic criteria for infection. The diagnosis is often set by 
multiple observations, such as the course and presentation of symptoms, x-ray studies, results of blood 
samples and joint aspirations. The most important findings are cultures, which also may be of multiple 
origins and thereby of varied clinical significance, e.g. wound swabs, blood or synovial fluid cultures, 
cultures of tissue samples and polymerase chain reaction (PCR) analyses for the 16S rRNA bacterial 
gen detection. Nevertheless, all of them may mislead clinicians due to false positive results 
(contamination) or false negative, occurring as a result of previous antibiotic treatment and poor 
sampling or management of samples. There are recommendations which may assist clinicians to 
establish the diagnosis119,121 but they are not entirely comprehensive and have been debated129. 
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The 2.2% incidence of PJI in primary fracture prostheses and 2.5% in secondary fracture prostheses 
(Study I) results in a significantly increased risk of PJI, compared with arthroplasty due to 
degenerative hip disorder (HR of 4.3 and 6.1 respectively). Several comorbidities are associated with 
increased risk of SSI after THA, such as obesity, diabetes ASA-score >3, bleeding, long surgery 
duration, pre-operative anaemia and rheumatologic disease53,130-134. While it was not possible to adjust 
for all these variables in our analysis, the higher mean age and the indication for surgery in both 
fracture populations indicates higher comorbidities and may be regarded as supportive of these 
previous findings. Conversely male gender was not previously described to be associated with 
increased risk of PJI after hip arthroplasty surgery. Also we have not found any analyses of risk of PJI 
after secondary hip prosthesis surgery. These patients’ highest risk of PJI can be explained by 
increased surgical trauma, longer duration of surgery, increased risk of bleeding, higher comorbidities 
and decreased preoperative general condition. 
The late occurring infections caused by HS predominantly occurred in the degenerative hip disorder 
population. An explanation of this finding is the overall shorter survival time of hip fracture 
patients135. 
The microbiology of infections in Study I showed a dominance of staphylococcus aureus and 
coagulase-negative staphylococci did not differ from previous findings60,133. Polybacterial infections 
were more common in degenerative hip disorder patients and some of these infections also included 
staphylococcus aureus and coagulase-negative staphylococci. We did not observe any infections 
caused by methicillin-resistant staphylococcus aureus and methicillin-resistant staphylococcus 
epidermidis. These antibiotic resistant bacteria are an increasing challenge in treatment of PJI136. 
The end results of PJI treatment in Study I showed that 27 patients (44%) had a resection arthroplasty 
as the final outcome (Table 11). Moreover, 22 patients (81%) of these patients were fracture patients. 
There are only few publications describing resection arthroplasty as outcome after PJI treatment. 
Westberg et al.54 reported an incidence of 29% in a prospective consecutive series of 184 hip fracture 
patients treated with arthroplasty (3 THAs and 181 bipolar HAs) and followed for 18 months. From a 
retrospective registry study, Teterycz et al.137 reported eight resection arthroplasties of 52 PJIs with a 
median follow-up of 2.3 years. Choi et al.138 described 10 resection arthroplasties in 93 infected THAs 
(8 fracture patients) in a study with a mean follow-up of 4.9 years. Finally Guren et al.56 reported a 
final result of 32% (12 cases of 37 PJIs) resection arthroplasties after PJI treatment of 519 HAs. In 
comparison, we found a higher incidence of performed resection arthroplasties. Differences in results 
could be explained by our longer follow-up time of minimum 5 years, the nation-wide coverage 
through SNPR and inclusion of secondary fracture prostheses. In our study, 56% of patients had a 
fracture diagnosis. Due to higher age and comorbidities in this population, compared with patients 
with a degenerative hip disorder, two-staged treatment is not always suitable for these frail patients. 
Table 11 
Final outcome of PJI in relation to indication for surgery 
 
 All PJIs 
Final outcomes of treatment 
 Resection arthroplasty Preserved prosthesis 2-stage revision 
 n=3807 n=62 n=27 (44%)** n=25 (40%) n=10 (16%) 
    Ab*  Ab*  Ab* 
Degenerative disorder n=1682 13 3 2 4 1 3 0 
Primary fracture n=1122 24 10 2 7 3 2 0 
Secondary fracture n=1003 25 10 0 8 2 5 0 
* = Lifelong antibiotic therapy 
**= 11 primary (performed as initial treatment) and 16 secondary (performed after failure of initial treatment strategy) 
   31 
Furthermore, treatment of fracture patients with debridement, antibiotics and implant retention more 
often results in failure56,139, which consequently worsen the outcome and may require a subsequent 
resection arthroplasty for resolution of the infection. 
These reported outcomes are observations from cohort studies and can only partially reflect a true 
nationwide outcome. Some countries have introduced SSI surveillance systems to monitor 
postoperative infection rates, including hip arthroplasty surgery. These registries may be a reliable tool 
and include clinical established PJI diagnoses, regardless of the different diagnostic criteria. In practise 
it is however difficult to establish complete registrations from all operating units. Surveillance through 
nation registries has also shown underreporting64,65. Sweden lacks an infection specific register and a 
model of national incidence surveillance, through cross matching of registries, with a subsequent 
medical records review has been proposed55. This method may be the most all-embracing and therefor 
result in nearly optimal assessment of the true incidence of PJI on a national level. However, until 
better reporting systems are in place, the assessment of clinical outcome of treatment of PJI will 
remain within the scope of cohort studies. 
Finally it is also important to mention the efforts to decrease rates of PJI. There are several guidelines 
that can potentially result in a significant decrease of PJI rate and, through earlier detection of 
infection, also improve outcome of treatment. Some of these recommendations are guidelines from: 
The World Health Organization (WHO), the Centre for Disease Control and Prevention (CDC)140, the 
Society for Healthcare Epidemiology of America (SHEA)141 and the National Institute for Health and 
Care Excellence (NICE) in the United Kingdom142. However a worldwide implementation of all 
suggested methods in each individual hip arthroplasty patient is challenging and possibly 
unachievable. 
In Sweden all 72 (as of year 2015) orthopaedic departments performing hip and knee arthroplasties 
participate in the multi professional initiative PRISS (Prosthesis Related Infections Shall be Stopped). 
The project was initiated by LÖF in 2008 and fully adopted by all units in 2013. A study of patient 
insurance claims showed that prior to 2008, orthopaedics was the specialty that had the highest rate of 
compensated claims (33%), with postoperative infection as the most common reason143. The objective 
behind initiation of PRISS was to reduce the incidence of infections by 50%. PRISS consists of four 
sections of recommendations, each reviewed and summarized by an expert group: 
1. Risk factors and preoperative optimization of patients 
2. Prophylactic antibiotic treatment 
3. Early detection and registration of infection 
4. Optimal surgical environment in hip and knee arthroplasty surgery 
The strength of this project was its wide approach and implementation through collaboration rather 
then imposing directives. This may have resulted in a broader implementation of recommended 
measures and an assessment of possible decrease of nationwide PJI rates is planned. 
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5.1.2 Air quality in surgical environment 
 
As shown in Study I, the consequences of PJI can be devastating. As described earlier, improvement 
of surgical environment through better air quality control prevents PJIs. This is achieved through 
appropriate ventilation and CAS. The number of staff in operating rooms also influences 
CFU-values144, as more individuals generate an increased amount of potentially bacteria carrying skin 
scales. Likewise, the behaviour and patterns of movement of operating room personnel also increases 
the amount of CFU in air145,146. Additionally, door openings contribute to contamination of air144. This 
equals out the pressure gradient between the operating room and surrounding spaces communicating 
with it, allowing contaminated air from outside to diffuse into the operating room. 
In Study II we compared two new CASs with currently used arrangement of a CAS system combined 
with two mobile LAF units. This selection of current CAS followed previous measurements in our 
department71. The need for further improvement of air quality resulted in addition of LAF units. As 
they were perceived to influence the working environment negatively, new efforts were put in place to 
evaluate other CAS systems.  
We did not achieve desired values of <5CFU/m3. The BARRIER® Clean Air Suit was our best 
performer with median CFU/m3 values of 12.0. Measurements of all three systems varied noticeably 
and this finding is consistent with previous studies43,144,147. Measurements with BARRIER® Clean Air 
Suit were later repeated and compared to another CAS system in our department with better and less 
variable values148 then in our study. The reported mean value of 7 elective arthroplasties was 7.0 
CFU/m3; all performed in a different operating room with likewise turbulent mixing ventilation, but 
with a higher air intake (996L/s vs. 620L/s in Study II). Moreover, these measurements were assisted 
by a mobile air filtration unit (Dopair, ATA Medical, Nantes, France), which delivered 360L of 
purified air per second, vs. TOUL’s combined 220L/s. The sizes of the operating room used in Study 
II and in this more recent assessment are comparable. Thus the results of the later study reflect the 
impact of ventilation, with improved CFU values achieved through more efficient dilution of air in the 
operating room. 
Cederlund and Tell recently performed a well-conducted analysis of the impact of ventilation 
systems70, which demonstrates the complexity of evaluation of the surgical environment. It started as 
an investigation ahead of the choice of a new ventilation system for the Karolinska Hospital in 
Huddinge, Stockholm. The challenge was approached in a comprehensive way: CFU measurements 
were conducted in multiple locations, air travel of micro particles was mapped, smoke was used to 
detect air-flow patterns and computer simulations, so called Computional Fluid Dynamics, were 
performed. Additionally the impact of heat generated by different equipment, on higher and 
previously not tested levels, was added to the analysis. This all-inclusive methodology resulted in new 
observations. The phenomenon of entrapment of air by shoulder-to-shoulder position of operating 
personnel resulted in slower dilutions of smoke and has not been described earlier. The positive and 
negative aspects of different ventilation systems were described and the investigation showed that 
sufficient LAF solutions increased the flexibility of choice of different CAS. 
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The observed outliers in both Study II and other studies144,147, can not directly be explained by 
variations in number of staff in the operating room, the individuals within each operating team, the 
specific procedure performed, door openings or the ventilation. The lower airflow in the operating 
room used in Study II may also be too weak to compensate for the irregular air streams created 
through the required higher physical activity in joint replacement surgeries. This difficulty reflects the 
complex and multifactorial relationship of real conditions of the surgical environment of operating 
rooms, where industrial standards therefore fail to predict the real outcome72. Therefor, in 
procurements of ventilation systems, The Swedish Board of Health and Welfare suggests definition of 
CFU/m3 level to be achieved during a standardised surgical procedure with a specified clothing 
system149. 
As mention earlier, different constellations, temperature gradients and diverse activities can create 
unforeseen air streams73. All these influencing factors and the consecutive variation of CFU values, 
indicates that we have to be cautious when comparing and discussing CFU values as a single outcome 
variable of air quality measurements in surgical environments. It can best be regarded as one of many 
tools of assessment of clinical settings. 
As change of ventilation systems in already existing units is rarely an alternative. The assessment 
presented in Study II, together with previous measurements71,72 and the subsequent study148, represent 
our departments continuous efforts of improvement of air quality in our surgical environment. 
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5.1.3 Patient insurance 
 
The Swedish Patient Safety Act, from 2011, obligates healthcare personnel to inform patients about 
the possibility of filing a malpractice claim150. According to the Swedish patient insurance scheme, 
claimants with SSI, resulting from IC, are entitled to compensation by LÖF.  
Our main finding in Study III was the overall high incidence of non-claimants. However, an absolute 
majority of filed claims were accepted for compensation by LÖF. This relation indicates on the one 
hand that those few patients that are claiming an injury from PJI are well informed about individual 
circumstances and eligibility for compensation, but on the other hand it also strongly suggests 
insufficiency in information from healthcare personnel to a large number of patients who do not make 
a claim. Although Study III involved patients who were diagnosed with infection before the Patient 
Safety Act was applied (from 2005 to 2010), the knowledge about the act still varies among healthcare 
personnel80. It is tempting to explain this with deficient knowledge of the Patient Injury Act among the 
personnel and not nationwide neglect. On the contrary, LÖFs initiation of the PRISS project, between 
2008 and 2013, may have increased the awareness of LÖF among healthcare personnel. Probably a 
combination of few faulty perceptions coincides. Except for a deficient awareness of legal obligations 
about patient information, other possible explanations may be incorrect impression of the system not 
being blame-free for practitioners, with a following unwillingness to report colleagues. Moreover, in 
cases of fast and relatively complication free recovery, healthcare personnel may not inform patients 
based on their own judgment, an assumption of certain cases not being severe enough to generate 
compensation. As shown in Study I, most PJIs are SSIs, resulting from IC. We believe that inclusion 
of infections caused by HS was limited by the postoperative observation time. Therefor HS infections 
cannot explain the high incidence of non-claimants.  
Age above 73 years and fracture diagnosis were two significant factors associated with lower rates of 
filed claims. Higher rates of non-claimants in the elderly correspond to previous findings78,151-154. To 
our knowledge, specific claim rates of THAs operated as a result of fractures have not been studied 
previously. Their decreased claim rate suggests that healthcare personnel may be less prone to inform 
elderly patients, with possibly higher comorbidity, about the insurance. As described in Study I, 
increased age and fracture diagnosis, possibly due to associated comorbidities, are also associated with 
poorer outcome after treatment of PJI. Conversely in Study III age was not observed to affect LÖF’s 
decisions of claims. Since the overall incidence of claims was low, it is not possible to draw any 
conclusions about outcome after PJI in the population of Study III. One possible explanation of our 
equal distribution of claims´ outcome is that the more frail patients never filed a claim. These results 
point towards several additive negative factors for elderly fracture patients. 
Another trend is the higher rate of claimants among patients operated in private hospitals. Their 
population of elective patients, commonly healthier and more aware of their rights and entitlements, 
may explain this. The private units may also have a better dialogue with their patients, which also can 
be a contributive factor. 
We chose the highest achieved educational level, as an indication of socioeconomic status, because of 
its accessibility in the population registers and conclusive definition. Income levels are difficult to 
match on lifetime earnings, family income or between monthly salaries and pensions. Higher rate of 
non-claimants in socioeconomic deprived areas has previously been described151. Classification of 
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these areas is controversial in their definition as well as the limited size of the studied population did 
not allow for such analysis. While we did not observe any significant association, a trend of higher 
education resulting in increased likelihood of filing a claim, was observed. Patients with higher 
education were younger, which could party explain our finding. 
The 21 county councils are responsible for organization of healthcare in Sweden and each hospital has 
a natural geographic and organizational belonging. Populations vary between counties with 
consecutively lower absolute numbers of PJIs in smaller counties. This fact strongly influenced our 
analysis of national differences of claim incidence, since every claimant had a large impact in majority 
of counties. Consequently no national difference in claims rates was observed above the county level. 
The highest and lowest incidences were identified in smaller counties. Only two counties, Västra 
Götaland (Gothenburg) and Stockholm, had more then 10 claimants (26 with 38 % claim rate and 23 
with 30 % claim rate respectively). 
LÖF’s compensations to individual patients vary considerably and are dependant on a many factors; 
e.g. disability, age, predicted loss of income and other reimbursements. However the total cost for the 
accepted claims was 8.8 million SEK until December 2016. Calculated for the non-claimants of the 
studied population, Swedish healthcare holds a potential reimbursement of 26.2 million SEK for these 
infections or above 80 000 SEK per patient, which is in line with LÖF’s own estimation of costs of 
about 90 000 SEK per reimbursed infected patient155. 
The Insurance Sweden consensus tables set a permanent disability level of 40% after a resection 
arthroplasty84. The disability level, beyond permanent resection arthroplasty, was not possible to 
assess with our study design in Study I. However referring to these consensus tables, 44% (27 of 62) 
of patients with PJI in Study I reached a 40%-level of permanent disability. In Study III, only 3.6% of 
claimants where acknowledged a compensation of above 30% disability (Figure 2). 
Through various patient safety projects, like PRISS, LÖF has taken on a roll as not only the insurer 
but also as an initiator of prevention of complications. This is facilitated by its reputation among 
healthcare personnel and patients, as well as its ownership by healthcare providers –the county 
councils. This unique constellation has a great potential for future improvements and evaluations of 
patient safety. 
In summary, results of Study III suggest that the elderly fracture population is not informed and helped 
in filing claims by healthcare personnel. Additionally, these patients may refrain from filing claims 
due to perception of the process as difficult and long lasting. The fact of a free of charge, two page 
form and the relatively short time to decision (70% within 8 months)85 is not obvious to the general 
population. It must be strongly suspected that most patients may not be aware that they have sustained 
an injury and thereby the system’s recognition of it. It is therefore of major importance to actively 
inform patients suffering from PJI about their legal right of filing claims to LÖF and provide 
assistance when needed. 
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5.2 THROMBOEMBOLIC EVENTS AND PROPHYLAXIS 
 
The most commonly used groups of TP drugs after elective THA in Sweden are LMWH and NOAC. 
In Study IV we examined unique nationwide cohort of 32 663 elective total hip arthroplasty patients. 
The study showed a significantly lower risk of VTE in the NOAC group, compared to the LMWH 
group. The efficiency of NOAC has been reported previously in several meta-analyses of 
symptomatic VTE, combining THA and total knee arthroplasty patients. They present adjusted results, 
favouring NOAC based on data of asymptomatic events111,156. Among recently published trials, only 
the large rivaroxaban phase IV XAMOS trial had symptomatic VTE as primary end point. A similar 
incidence of 0.3% was reported in THA patients with rivaroxaban TP, as compared to standard-of-
care (OR 0.43, CI 0.24 - 0.80)105 constituting of several different TP regimens as the comparator. 
Clinical trials often fail to adhere to standardised definitions and reporting of bleeding 
complications157. Direct comparison is therefore difficult. However analysis of bleeding is important 
as safety assessment of TP. The selection of a TP regimen relies on the balance between the desire to 
minimise thromboembolic events and the attempt to reduce the risk of bleeding. The 
recommendations regarding assessment of bleedings usually include measures of blood loss, 
transfusions, fall in haemoglobin levels or bleeding leading to alternation or cessation of 
treatment157,158. These events can be assessed in clinical trials but are more difficult to evaluate in 
register studies. On the contrary, register studies offer an opportunity to include the larger populations 
needed to study infrequent adverse events. In Study IV there was no significant difference in risk of 
bleeding events between LMWH and NOAC. This is supported by the RE-NOVATE I and II 
dabigatran trials102,103 and the rivaroxaban trials RECORD I and II159, the XAMOS trial105, as well as 
several meta-analyses110,156. Contrarily other meta-analyses found an increased incidence of 
bleedings111,112. Due to the high completeness of our registers, we consider the risk of a significant 
amount of missed bleedings to be negligible. Rather the opposite can exist, bleedings not related to TP 
may have been registered. Compared to other studies92,108,114,159,160, the wide-ranging bleeding 
definition in Study IV results in a negative influence on our safety analysis but with equal distribution 
in both TP groups. 
During the last 3 years of the study 25% of patients were prescribed NOAC. A new, extended cross 
matching would be needed to assess today’s distribution. However, with time NOACs have become a 
less novel choice and it is therefor probable their share as TP agents has increased. On the contrary 
National Joint Registry reports 24% of patients receiving NOAC as TP after primary THA in 201622. 
The difference in duration of TP between the two groups reflects the absence of consensus and 
national guidelines. Our large study population allowed for a separate subanalysis of this occurrence 
in the larger LMWH group and showed that the treatment length did not influence the risk of VTE. In 
Figure 3 a pattern of treatment lengths can be observed, which follows regimens of TP duration of up 
to one, two and four weeks with LMWH and 5 weeks with NOAC. This can be interpreted as a 
reflexion of the various established regimens of TP and likewise tailored sizes of prescribed packages 
of medications, supplied by the pharmaceutical companies. Several earlier studies reported a 
prolonged risk of VTE and suggested a need for extended TP104,161-164. Out of the more internationally 
acknowledged guidelines, NICE99 recommends extended TP of 28 to 35 days postoperatively, while it 
is only suggested by ACCP93. A recent Cochrane review concluded that there is moderate quality 
evidence suggesting extended duration of TP but it should be considered for patients undergoing 
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THA, although the benefit should also be weighed against the increased risk of minor bleeding165. On 
the contrary several studies report low rates of VTE with short duration TP and fast-track 
surgery166-168. Patients suitable for fast-track surgery are usually younger and healthier168 and thereby 
able to take greater advantage of the VTE-preventing effect of faster mobilisation. A partial 
explanation to our finding of non-increased risk of VTE with short duration of TP in the LMWH 
group may lie in our exclusion criteria. The elimination of patients who did not purchase their TP 
medications within 10 days after operation, had a documented VTE five years prior to the operation 
and were prescribed LMWH, NOAC or warfarin 6 months preoperatively, most probably decreased 
comorbidity in our cohort. This could result in faster mobilisation and recovery in the studied 
population and conclusively a decreased overall risk of VTE in these patients. 
The choice of TP after primary THA remains a subject of debate. Advances in anaesthetic 
techniques92 and early mobilisation166 are suggested to reduce the background risk for VTE93 and 
thereby allow for use of less potent TP agents, such as ASA. This may decrease the risk of bleeding 
and wound complications169-171, as well as being a more cost-effective alternative172. Although earlier 
usage of ASA as TP was debated, its popularity increased after the PEP trial98. This trial has been 
criticised as it allowed for parallel usage of other TP agents together with ASA. Nevertheless recent 
knowledge173,174 and guidelines support the role of ASA in prevention of VTE. Various associations 
have changed their view on TP with ASA, which is now recommended by the American College of 
Chest Physicians (ACCP)93, the American Academy of Orthopaedic Surgeons (AAOS)175 and the 
British Hip Society176. However, the NICE guidelines do not recommend ASA as a sole agent with 
concern of limited literature comparing ASA with other TP agents99,172. The heterogeneity of patients 
undergoing THA surgery is difficult to cover by one optimal regimen and individualised therapies can 
be applied177. These are however difficult to establish. Among resent publication, one cohort study 
included 1 152 low-risk patients operated with a hip or knee arthroplasty and reported an incidence of 
symptomatic VTE of 1.1%, with combined aspirin and pneumatic compression treatment as a 
multimodal regimen of TP178. A large British register study of 108 584 patients found a significantly 
lower mortality with LMWH, compared to aspirin while the outcome of VTE (1.6% vs. 1.7% 
respectively) did show any significant differences160. A trial of elective THA patients with initial 10 
days TP with dalteparin, followed by randomisation between continued TP with ASA or dalteparin for 
a total time of 28 days, reported a lower incidence of VTE in patients assigned to continued therapy 
with ASA then dalteparin (0.3% vs. 1.3%). The incidence of clinically significant bleeding was also 
lower in the ASA group (0.5% vs. 1.3%)179. However these results are based on only 778 subjects as 
the trial was stopped due to slow enrolment. In conclusion, there is evidence of ASA’s effectiveness 
and safety180 but limited by variations of comparison, quality of studies, administered doses and 
regimens with combinations of agents and multimodal approaches178,179,181-184, incomplete follow-
up185, and risk of reversed causality186. The low incidence of VTE in Study IV can be compared to 
previous publications but, as the definitions of bleedings vary considerably between both cohort and 
register studies, safety outcomes should be compared with caution and attention to their definitions. 
Study IV is a unique and large study, with nationwide coverage and analysis of effectiveness of TP, 
comparing NOAC and LMWH as postoperative TP after primary THA performed due to 
osteoarthritis. Moreover, the study was performed independently of any financing or affiliation with 
manufacturers or other interest groups. Our analyses showed a superiority of NOACs effectiveness in 
VTE prevention, reducing the risk of VTE by more than 50%, compared to LMWH, with remained 
safety profile. The quality of our registers and the large cohort reassures clinical generalizability of our 
results. 
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5.3 LIMITATIONS 
 
Each of the studies of this thesis has its limitations. The main ones are presented below: 
 
Study I 
The long study period of 10 years spans over a period of many inconclusive regimens and is the main 
limitation of this study. No consensus or defined diagnostic criteria were used to ensure early 
detection of PJIs. Moreover surgeons decided on treatment regimen based on their own experience 
and opinion, which in many cases may have resulted in a deficient approaches, compared to current 
standards. This is supported by the comprehensive review of patients´ records. Inadequate and varied 
series of lavage and debridement were often used to salvage the implants. This may have resulted in 
higher frequencies of treatment failure and/or resection arthroplasties. On the contrary, nationwide 
register studies are limited by poor quality of data and deficient reporting from surgeons64,65. 
 
Study II 
The Mertex CAS were supplied as brand new for this study, while in everyday practice these are used 
as washed (up to 50 times), reusable CAS. This can have a negative effect on their permeability of 
airborne particles. Consequently, the measurements of the daily used Mertex system may show even 
higher CFU values. Additionally, condensate on the lids of 25 measurements may have been avoided 
by allowing for longer time of adaptation to room temperature, after being taken out from their cold 
storage. 
Comprehensive evaluation of surgical environments requires several different measuring methods and 
computing models. Study II presents a method for assessment and improvement of existing settings 
but its direct application on future projections and erections of operating rooms, ventilation systems or 
procurements of CASs should be done with caution. 
 
Study III 
As mentioned, the population of this study acquired their infections before both the Patient Safety Act 
of 2011 and the completion of introduction of PRISS. Despite the fact that the objective of PRISS is to 
decrease the incidence of PJI, and not to implement better obedience of the law, the implementation of 
PRISS may have resulted in higher awareness and knowledge of LÖF. Therefore these results do not 
directly reflect the current settings. However, we have reasons to believe that the knowledge of LÖF is 
deficient among healthcare personnel80. Additionally the overall annual increase of filed claims to 
LÖF of about 2%81 suggests continued low rates of filed patient claims. 
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Study IV 
The incidence of VTE and adverse events may have been decreased by our exclusion criteria, since 
patients with documented VTE five years prior to the operation and patients with prescribed LMWH, 
NOAC and warfarin 6 months preoperatively were excluded. Furthermore exclusion of patients, who 
didn’t purchase their TP medications within 10 days after operation, may have excluded individuals 
with prolonged wound drainage65,108,109 or higher comorbidity. Based on the high number of 
observations we think that there is a low probability for skewed distribution of possible confounders 
between the NOAC and the LMWH groups. 
All patients where postoperative prescription data on TP was absent were excluded, consequently 
withdrawing 16 899 patients from this analysis. As this data is automatically transferred to SPDR, and 
after discussing the matter within the Swedish Hip and Knee Association (representing the majority of 
THR surgeons in Sweden) we are feeling certain that large proportion of these patients were provided 
a supply of TP medications on discharge, consequently bypassing the SPDR. No further analysis of 
these patients was performed and their impact on the true national incidence of VTE after THA is 
unknown. 
There may be residual confounding in patients’ demographic and clinical characteristics. For example 
patients with NOAC treatment had higher comorbidity according to the Elixhauser score. According 
to previous studies, this should have influenced results with higher incidence of VTE in the NOAC 
group92,94. The higher incidence of cemented fixation among the NOAC patients may also partly 
reflect the higher comorbidity in this group, as the preferred fixation for patients of higher age and 
comorbidities. However, the role of fixation on VTE, beyond the immediate postoperative period, is 
debated. Cemented fixation is reported as both associated with higher187 and lower188 incidence of 
VTE. Any association of cemented fixation and increased risk of VTE would consequently 
disadvantage NOAC. 
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6 CONCLUSIONS 
 
 
§ Patients with a displaced femoral neck fracture treated with primary or secondary fracture 
arthroplasties have a greater risk of PJIs and display worse outcomes compared with patients 
with a total hip replacement due to degenerative hip disorders. 
- Study I 
 
§ Single-use polypropylene clothing systems can replace mobile laminar airflow unit-assisted 
reusable mixed material-clothing systems. Measurements in standardized laboratory settings can 
only serve as guidelines as surgical environments in real settings present a much more difficult 
challenge. 
- Study II 
 
§ The incidence of patient claims of PJI is low but claims are usually accepted when filed. 
Healthcare personnel should increase their knowledge of LÖF and the Patient Injury Act to 
inform patients about possibilities of eligible compensation. 
- Study III 
 
§ Thromboprophylaxis with NOAC extending for a minimum of 28 days is a safe and more 
effective regimen than LMWH for the majority of patients undergoing elective primary THA 
surgery. It reduces the incidence of VTE by 50% with no difference in bleedings, reoperations 
and mortality. 
- Study IV 
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7 FUTURE PERSPECTIVES 
 
When thinking of future perspectives, it is hard to not be inspired by the upcoming possibilities of 
artificial intelligence (AI). The first study on its possible implementation in orthopaedics has already 
been published189. Cross matching of registries for outcomes and their associations can potentially also 
be carried out by machine-learning algorithms, perhaps resulting in previously unidentified predictors. 
While further development and evaluation of implementation of these possibilities is needed, the 
suggested studies below may be undertaken much sooner. 
 
Prosthetic hip infections and patient insurance 
Arthroplasties included in Study I and III were performed prior to the Patient Safety Act and complete 
implementation of the PRISS project. An evaluation of the “post-PRISS” infection rate is planned. As 
PRISS mainly deals with prevention, it does not include recommendations regarding treatment. 
However it does recommend follow-up and early detection of infection, which in turn increases the 
likelihood of successful treatment. Therefore PRISS may not only have an impact on infection rates 
but also on outcome of treatment and consequently any acquired permanent disability. These are 
possible aspects of future studies of great interest to the suffering patients and insurance providers. In 
this context, the possibly increased awareness of LÖF, through PRISS, as well as the impact of the 
Patient Safety Act could also be assessed.  
In a more distant future and stipulating higher rates of PJI claimed, feedback of patients’ disability 
levels after treatment of PJI (as assessed by LÖF’s expert reviews) could facilitate evaluation of 
different treatment regimens. 
 
Thromboembolic events and prophylaxis 
More studies are still needed to determine the best TP agent. Possibly there is not one but rather 
several treatments which should be distinguished for different groups of patients. Register studies 
capture large populations but fail to adjust for the variability of studied subjects. On the contrary, even 
large trials fail to include enough amount and diversity of patients. A large nationwide cluster-
randomisation trial may have the potential to identify the right agents, were each hospital is a cluster 
treating patients with the allocated TP agent. A setting of different types and sizes of hospitals enables 
inclusion of satisfactory amount of subjects, through a catchall approach. Exclusion criteria could be, 
as far as possible, limited to obvious contraindications, e.g. advanced kidney failure. Randomisation 
of the different TP agents on hospital level facilitates adherence to the new local treatment regimens. 
Simultaneously it would enable standardised recording of patient factors and outcomes, particularly 
the bleeding and wound complications.  
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8 SAMMANFATTNING PÅ SVENSKA 
De kliniska resultaten efter höftproteskirurgi är mycket goda idag. Livskvalitén kan höjas avsevärt för 
patienter med långdragna och invalidiserande smärttillstånd. Samtidigt är det även en mycket bra 
behandlingsmetod inom den akuta frakturkirurgin. Den låga komplikationsfrekvensen medför en 
ständig ökning av antalet operationer. Årligen behandlas över en miljon patienter världen över och 
ingreppet har utnämnts till århundradets operation. Denna utveckling, resulterar samtidigt i ett 
stigande antal komplikationer. Näst efter proteslossning och luxation är postoperativa, s.k. 
periprostetiska infektioner, den vanligaste och samtidigt den allvarligaste komplikationen för den 
drabbade individen. Behandlingen av infektioner är inte alltid framgångsrik och kan resultera i en 
livslång invaliditet. Venös tromboembolism, som utgörs av lungemboli och djup ventrombos, är den 
vanligaste medicinska komplikationen. Tre olika aspekter av infektioner (Studie I – III) och 
tromboskomplikationer (Studie IV) efter höftproteskirurgi diskuteras i denna avhandling. 
Studier i avhandlingen 
I studie I och II studerades patienter opererade på Södersjukhuset i Stockholm. Studie III och IV 
grundar sig på data ur nationella hälso- och kvalitetsregister. 
Studie I: 3 884 patienter, opererade med höftprotes mellan 1996 och 2005, följdes i ett lokalt register. 
Patienter som erhöll höftprotes pga. degenerativ höftledssjukdom jämfördes med primära och 
sekundära (opererade pga. haveri av tidigare frakturbehandling) frakturproteser. Antalet 
periprostetiska infektioner och dess behandling samt utfall analyserades. 
Studie II: Luftburna bakterier är en peroperativ smittokälla och god luftkvalité är därför ett krav för 
att erhålla en låg peroperativ infektionsfrekvens. Tre olika operationsdräkter jämfördes under 37 
pågående ledprotesoperationer, genom 244 mätningar av mängden bakteriebärande luftburna partiklar. 
Studie III: Alla patienter som behandlas inom svensk offentlig sjukvård är försäkrade i 
patientförsäkringen, LÖF. Tidiga och fördröjda periprostetiska infektioner klassificeras som regel som 
undvikbara vårdskador och patienterna har därmed möjlighet att få ersättning. Sjukvården är dessutom 
skyldig att informera patienterna vid uppkomst av vårdskada och möjligheten att anmäla denna till 
LÖF. En tidigare fastställd kohort av 441 periprostetiska infektioner jämfördes med LÖFs register 
över anmälda patientskador. Rapporteringsgraden till LÖF och utfall av anmälningarna studerades. 
Studie IV: Genom trombosprofylax eftersträvas både en effektiv och säker behandling. Studien 
jämförde lågmolekulärt heparin och nya orala antikoagulantia, genom analys av effektivitet (utfall av 
lungemboli och djupa ventromboser) och säkerhet (utfall av blödningskomplikationer, reoperationer 
samt mortalitet) hos 32 663 patienter opererade med elektiva höftproteser. 
Konklusion 
Jämfört med patienter opererade pga. degenerativ höftledssjukdom, löper patienter med höftfraktur 
(opererade med primära eller sekundära höftproteser) en signifikant högre risk att drabbas av en 
periprostetisk infektion (0,4% vs 2,1% respektive 2,5%). Även utfallet av infektionsbehandlingen hos 
dessa patienter är sämre med en högre andel permanenta slinkleder, där höftprotesen avlägsnas för att 
behandla infektionen. Jämfört med artrospatienter, uppvisar frakturpatienterna därtill en signifikant 
lägre anmälningsfrekvens till LÖF (13% vs 28%). Den generella anmälningsgraden är låg (25%) men 
de flesta anmälningarna bifalles (96%). Detta antyder bristfällig kännedom om LÖF inom sjukvården. 
Vi uppnådde inte de eftersträvade låga nivåerna av luftburna bakterier men engångsdräkter tillverkade 
av polypropylen var överlägsna de två andra undersökta flergångsdräkterna. Förbättring av 
luftkvalitén i befintliga operationssalar kan uppnås genom byte till engångskläder av polypropylen. 
Behandlingsregim längre än 28 dagar med nya orala antikoagulantia halverar förekomsten av 
postoperativ venös tromboembolism hos patienter opererade med elektiv höftprotes. Den oförändrade 
säkerhetsprofilen antyder dessutom att en majoritet av höftprotespatienterna bör erbjudas förlängd 
profylax med nya orala antikoagulantia. 
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